Index

Terms that begin with numbers are indexed as if the number were spelled out; e.g., "3D models" is located as if it were spelled "ThreeD models."

A-77003
  structure-based design, 437–438
A-80987
  structure-based design, 438, 439
A-306552,675
Absolv program, 389
Absorption, distribution, metabolism, and excretion (ADME)
  as bottleneck in drug discovery, 592
  estimation systems, 389-390
  molecular modeling, 154–155
Absorption, distribution, metabolism, excretion, and toxicity (ADMET), 389
  and druglikeness screening, 245
  and virtual screening filter cascade, 267
ABT-418,808–810
ABT-627,811–812
ABT-773,876
Academic databases, 387–388
Acarbose, 849
Accelrys databases, 384–385
Accord, 377,385
Accord Database Explorer, 385
Acebutol
  renal clearance, 38
ACE inhibitors, 718,881
  asymmetric synthesis, 807,809
  comparative molecular field analysis, 151–153
  conformationally restricted peptidomimetics, 640–641
  molecular modeling, 131, 132–133, 145
  multisubstrate analogs, 746–748
  receptor-relevant subspace, 204
  structure-based design, 432–433
  transition state analogs, 650–651
Acetic acid
  CML representation, 372
Acetylcholine, 772
  cation-π bonding, 724–725
  conformationally restricted analogs, 697–698
  muscarinic agonist analogs, 143–144
Acetylcholinesterase inhibitors, 718
  CoMFA study, 58–59
  pseudoirreversible, 772–774
  substrates from acetylcholine analogs, 697–698
  target of structure-based drug design, 449–450
  volume mapping, 140
  X-ray crystallographic studies, 482
N-Acetylcysteine
  toxicological profile prediction, 838,840
Acetylsalicylic acid (aspirin), 762–763
Acquire database, 386
Actimomycin D
  thermodynamics of binding to DNA, 183
Actinoplanes utahensis, 878
Active Analog Approach, 58, 60, 639
  flow of information in, 146
  and molecular modeling, 134, 151
  and systematic search, 144–145
Active-site directed, irreversible inhibitors, 755
Activity
  binding affinity contrasted, 131–135
Activity-guided fractionation, 597
Activity similarity, 255
Acyclovir, 717, 719, 756
Acyl halides
  filtering from virtual screens, 246
ADAM
  geometricl combinatorial search, 295
ADAMs, 652
ADAPT, 53
Adenosine deaminase inhibitors, 717
  mass-spectrometric screening for ligands to, 604
  transition-state analogs, 750–752
  X-ray crystallographic studies, 482
S-Adenosyl-L-homocysteine, 733,740
S-Adenosyl-L-methionine, 733
ADEPT suite, 225,226,237
ADME studies, See Absorption, distribution, metabolism, and excretion (ADME)
ADMET studies, See Absorption, distribution, metabolism, excretion, and toxicity (ADMET)
ADP analogs, 763–764
Adrenaline, 885,886
β-Adrenoreceptor antagonists, See β-Blockers
Afferent, 387
Affinity calculation, 118–122
Affinity capillary electrophoresis-mass spectrometry, 599–600
Affinity chromatography-mass spectrometry, 598599
Affinity grids, 292–293
Affinity labels, 756–759, 760–764
Affinity NMR, 571
2-AG, 853
AG31
  structure-based design, 428–429
AG85
  structure-based design, 428
AG331
  structure-based design, 428–429
AG337
  structure-based design, 428

AG2034
structure-based design, 431–432
AG2037
structure-based design, 431–432
Agenerase
structure-based design, 440, 441
Agent, 398
Aggregate concept, in molecular modeling, 90–91
AIDS, See HIV protease inhibitors
AIDS database, 386
AIMB, 255
ALADDIN, 259,363
in molecular modeling, 111, 113
Alaninates
binding to chymotrypsin, 35
Alanine racemase inhibitors, 717
Alcohol dehydrogenase
QSAU studies, 5
Alcohols
pharmacophore points, 249
QSAU studies, 27–29
Alcuronium, 856,857
Aldehydes
filtering from virtual screens, 246
Aldose reductase inhibitors
novel lead identification, 321
target of structure-based drug design, 447–449
Aldosterone, 746
Alkyl amines
polarization energy, 173
protonation, 179–180
Alkyl chain homologation analogs, 699–704
Alkyl halides
filtering from virtual screens, 246
Allinger force field, 80
Allosteric effectors
of hemoglobin, 421–424
and lock-and-key hypothesis, 5
N-Allylmorphine, 850
Almond program, 202
Alogp, 390
Alpha-amylase, 482
N-Alpha-(2-naphthylsulfonylglycyl)-4-amidinophenylal [NAPAP] piperidide
structure-based design, 442, 444
Alprenolol
renal clearance, 38
Altracurium
lead for drugs, 856–858
AM1 wave function, 15, 102
AM404, 854
Amaryllidaceae (snowdrops, daffodils, etc.), 892
Amastatin, 738
AMBER energy function, 264, 307–308
performance in structure prediction, 315
seeding experiments, 319
AMBER/OPLS force field, 80, 81,103
in molecular modeling, 118
American mandrake, drugs derived from, 865
Amides
enzyme-mediated asymmetric bond formation, 804–805
exchange rates/temperature coefficients, in NMR, 512
pharmacophore points, 249
Amines
pharmacophore points, 249, 250
Aminidine
pharmacophore points, 249
Amino acid mimetics, 640
Amino acids
chemical modification reagents, 755
chirality, 784
classical resolution, 797
conglomerate racemates, 802–803
Aminoacyl-tRNA synthetases
binding of alkyl groups to, 8
γ-Aminobutyric acid aminotransferase (GABA-T) inhibitors, 488, 718, 766–767
γ-Aminobutyric acid (GABA), 766
analogs, 690
geometric isomer analogs, 705–706
molecular modeling, 149
7-Aminocephalosporanic acid (7-ACA), 871,874
2-Amino-3-chlorobutanoic acid
nonclassical resolution, 803
Aminoglutethimide, 717
chromatographic separation, 792
classical resolution, 798, 799
6-Aminopenicillanicacid (6-APA), 869,870
Aminopeptidases
transition state analog inhibitors, 652
8-Aminoquinolines, 888–889
Amiodarone, 884,885
Amitriptyline, 692
Ammi visnaga (toothpick plant), 883
Amoxycillin, 869,870
AMP analogs, 764
Ampicillin, 869, 870
Amprenavir, 648,659
structure-based design, 440, 441
α-Amylase
X-ray crystallographic studies, 482
β-Amyloid
X-ray crystallographic studies, 482
Analog design, 687–689
alkyl chain homologation, 689, 699–704
bioisosteric replacement and nonisosteric bioanalogs, 689–694
chain branching alteration, 689
fragments of lead molecule, 689,707–710
interatomic distances variation, 689, 710–712
limitations of, 532
rigid or semirigid analogs, 689,694–699
ring-position isomers, 689
ring size changes, 689
stereochemistry alteration and design of stereoisomers/geometric isomers, 689, 704–707
substitution of aromatic ring for saturated, or the converse, 689
Anandamide. 853
Anchor and grow algorithm, 294,296
AND logical operator, 406
Androgen receptor
X-ray crystallographic studies, 482
Angiotensin-converting enzyme (ACE),650,881. See also ACE inhibitors

active site molecular modeling, 131,132–133
target of structure-based drug design, 432–433
Angiotensin I, 432–433,746,881
Angiotensin II, 432, 746, 881
non-peptide antagonists, 668–669,670
Anhydrides
filtering from virtual screens, 246
Anomalous Patterson maps, 477
Antiasthma drugs
natural products as leads, 883–886
Antibacterial enzyme inhibitors, 717
Antibiotic drugs
natural products as leads, 868–878
Antibiotic resistant pathogens, 770
Anticancer drugs
enzyme inhibitors, 717, 718
molecular modeling, 151
natural products as leads, 858–868
Anticoagulant protein C
X-ray crystallographic studies, 482
Anticoagulants, 882–883
Antifolate targets
structure-based design, 425–432
Antifungal enzyme inhibitors, 717
Antiparasitic drugs
natural products as leads, 886–891
Antiprotozoal enzyme inhibitors, 717
Antisickling agents, 419–421
Antiviral enzyme inhibitors, 717
Apamin
molecular modeling, 124
AP descriptors, 55, 56
Apex, 256,387
Apex-3D, 60
Application tier, 392,398,406
Aquaporin 1
X-ray crystallographic studies, 482
Aqueous solubility
and structure-based design, 408
Arabidopsis thaliana
genome sequencing, 344
Arabinose binding protein
genetic algorithm study of docking, 88–89
Arachidonic acid, 762, 763
Arecoline analogs, 693–694
Argatroban
structure-based design, 442,444
Arginase inhibitors, 736–737
Arginine
chemical modification reagents, 755
Aromatase inhibitors, 717, 770
Aromatic-aromatic interactions, 286
Aromatics
analogs based on substitution of aromatic for saturated ring; or the converse, 699–704
growth inhibition by, 38
molecular comparisons, 139
ArrayExpress, 345
Artabotrys uncinatus, 887
Arteether, 887
Artemether, 887–888
Artemisia *annua* (sweet wormwood), 886,888
Artemisinin, 849,886–888
Artificial intelligence, 398
Artificial neural networks
for druglikeness screening, 247–248,250
in molecular modeling, 126
in QSAR, 53, 62, 67
for structural genomics study, 353
Arylsulfonamidophenethanolamine analogs, 703
p-Arylthio cinnamide antagonists, 566–567
ASCII (American Standard Code for Information Exchange), 398
Ascomycin
binding to FKBP, 552, 553–554
Asinex catalog, 385
Aspartate transcarbamoylase (ATCase) inhibitors, 743–744
Aspartic acid
chemical modification reagents, 755
Aspartic peptidase inhibitors
transition state analogs, 647–649
virtual screening, 315
Aspergillus *alliaceus,* 855
Aspergillus nidlans, 878
Aspergillus *terreus,* 879
Asperlicin
fragment analogs, 708
lead for drugs, 855–856
Aspirin, 762–763,764
Assay Explorer, 387
Association thermodynamics
drug-target binding, 170–171, 177–179
Asymmetric centers, 784,785
Asymmetric synthesis, 784, 804–820
enzyme-mediated, 804–807
Asymmetric transformation
crystallization-induced, 798–799
Atenolol, 882
renal clearance, 38
Atom-atom mapping, 380,398
Atom-centered point charges, 101–102
Atomic counts, 54
Atom list, 398
Atom-pair interaction potentials, 120
Atom stereochemistry, 365,398
Atom-type E-State index, 26
Atorvastatin, 744, 880
ATP analogs, 763–764,765
H^+,K^C-ATPase inhibitors, 718
Na^+,K^+-ATPase inhibitors, 718
Atracurium, 857,859
Atrasentan (ABT-627), 811–812
Atrial natriuretic factor, 650
Atrolactate, 762
Atropine
lead for drugs, 851
Augmentin, 869
Aura-Mol, 388
AUSPYX, 387
AutoDock
affinity grids, 293
explicit water molecules, 303
flexible ligands, 263
Lamarckian genetic algorithm, 299
Monte Carlo simulated annealing, 297
protein flexibility, 301
Automap, 398
Available Chemicals Directory (ACD), 385,386
virtual screening application, 254
Avermectins, 891,892

Azathioprine, 717
Azithromycin, 848,849, 875–876
Aztreonam, 873–874

Babel, 372
Baccatin 11,863
Backtracking, 382,399
in virtual screening, 67
Bacterial luminescence inhibition by ROH, 27
Bacterial natural products, 848, 893
Bacteriorhodopsin
electron cryomicroscopy, 612
homology with **GPCRs**, 123, 150
Barnard Chemical Information, 388
Bcl-xL
target of spin-label **NMR** screening, 573–574
BCUT descriptors
defined, 399
estimation systems, 388
for molecular **similarity/diversity** methods, 193–194, 203–204
with pharmacophore fingerprints, 223–224
for target class-focused approaches, 228–229,232–233
BCX 1812
structure-based design, 452
BDE index, 11
Beilstein Database, 362,385
Beilstein Online, 385
Benign prostatic hypertrophy
expression probabilities, 343
Benzamidines
inhibitors of trypsin, 120
Benzene
electron density, 135
intermolecular interactions, 174
Benziodarone, 884
Benzomorphans, 850
Benzopyran
enzyme-mediated oxidation, 806
Benzylpenicillin, 868,870
(R)-2-**Benzylsuccinic** acid, 746
Bestatin, 652, 654, 728
β-Blockers, 881–882
enantiomers, 786
nonrenal clearance, 39
renal clearance, 38
Bezafibrate, 422
BIBP 3226,670,673
BIBR 953
structure-based design, 443, 448
BIBR 1048
structure-based design, 442, 443
BIBU52, 213
Bifenthrin, 41, 42
Binary data, 373,399
Binary QSAR, 4
Binding afiinity, 286
activity contrasted, 131–135
calculation, 118–122
Binding constant, 286
Binding property classes, 192
Binding site models, 130
Bioactivity databases, 386
Bioafiinity screening
by electrospray FTICR MS, 601–603
Bioavailability, 716
BioCatalysis database, 384
Biochemical force fields, 175–176
Bioinformatics, **333–337**
databases, tools, and applications, 345–349
defined, 399
and functional genomics, 338340
future developments, 354
and sequences, 364
standardization, 337
and structural genomics, **352–354**
for target discovery, 335, 338–345
Bioinformatics knowledge model, **349–352**
Bioisosteric replacement analogs, 689–694
Biological data, 399
Biological evaluation
in structure-based design, 419
BioScreen NP/SC, 385
BIOSTER database, 202,384
Biosterism, 689–690
Biotin
genetic algorithm study of docking to streptavidin, 89
interaction with streptavidin, 181–183
Biotransformations database, 384
Biphenyls
privileged structures, 252
Biphenyl tetrazole, 231
BIRB-796
structure-based design, 458–459
Bisubstrate analog enzyme inhibitors, 741–742
Bitset, 399
BLAST (Basic Local Alignment Search Tool), 347
BLEEP potential, 312
performance in structure prediction, 314
BLOB (Binary Large Object) data type, 399
Blood substitutes
structure-based design, 424
BMS-193884,674,676
BMS-247550,864,865
Bohm scoring function, 264
Boltzmann law, 93,310311
Boltzmann probability, 94
Boltzmann weighted average, **97, 98**
Bond stereochemistry, 365, 399–400
Born-Oppenheimer approximation, 79
Born-Oppenheimer surface, 85
Bothrops jararaca (pit viper), 881
Bovine liver DHFR, QSAR inhibition studies, 34
Bovine pancreatic trypsin inhibitor
long range electrostatic effects, 177
Bradykin, 746,881
targeted library design, 69, 70
BRIDGE, 113
BRN (Beilstein Registry Number), 378, 400
Bromoaspirin, 763
Bromobutide, 42
Bromperidol
HIV protease inhibitor, 111, 112
Bryostatin-1, 868,869
Bufuralol
renal clearance, 38
Bugula neritina, 868
Building block hypothesis, 88
Bupivacaine hydrochloride, 805, 806
classical resolution, 795, 796
Buprenorphine, 850–851
Business rules, 378,400,403
BW12C
antisickling agent, 419–420
BW1476U89, 742–743

CACTVS, 254
Calabash curare, 856
Calcineurin A
  X-ray crystallographic studies, 483
Cambridge Crystallographic Database, 110
Cambridge Structural Database, 354,387
  X-ray crystallography application, 479
CAMP
  molecular property visualization, 137
D-Camphor
  connection table, 367
  tabular molecular file formats, 370–371
cAMP phosphodiesterase II inhibitors
  molecular modeling, 130
Camptotheca acuminata, 860
Camptothecin
  drugs derived from, 860–861
Candoxatril, 815,818
Cannabinoids
  lead for drugs, 852–854
Cannabis *sativa,* 852
Canonical numbering, 378,400
Capillary electrophoresis
  for enantiomer separation, 787
Capsaicin, 854
Captopril, 646,650,746–747, 881
  asymmetric synthesis, 807, 809
  structure-based design, 432–433,434
Carbamates
  pharmacophore points, 249
Carbenin, 849
Carbo index, 202
Carbonic anhydrase inhibitors, 718
  4-fluorobenzenesulfonamide binding to, 538
  molecular modeling, 120
  virtual screening for, 316
Carbonic anhydrase II inhibitors, 718
  novel lead identification by virtual screening, 320
  X-ray crystallographic studies, 483–484
Carboxylic acids
  pharmacophore points, 249
  privileged structures, 252
Carboxypeptidase A
  similarity of active site to ACE, 433,746–747
Carboxypeptidase inhibitors
  conformational changes on binding, 261
  genetic algorithm study of active site, 89
  molecular modeling, 116
Cardiovascular drugs
  natural products as leads, 878–883
CART, 67
Cascade clustering
  with molecular similarity/diversity methods, 205
CASETox, 246
CAS Numbers, 378,400
CAS ONLINE, 361
  similarity searching, 383
Caspase-1 inhibitors
  target of structure-based drug design, 443
  transition state analogs, 655
Caspase-3 inhibitors
  transition state analogs, 655
Caspase-7 inhibitors
  transition state analogs, 655
CASP experiment (Critical Assessment of techniques for protein Structure Prediction), 123,353
Caspofungin, 848,878
CASREACT, 385
CAS Registry, 363,385
Catalyst (program), 259
  3D shape-based searching, 199,201
  for novel lead identification, 321
Catalyst/Hip/Hop, 60
Catalyst/Hypo, 60
Catechol methyltransferase
  X-ray crystallographic studies, 484
CATH, 353
  X-ray crystallography application, 494
Catharanthus *roseus,* vinca alkaloids from, 858
Catharanthus (vinca) alkaloids, 858–860
Cathepsin B
  transition state analog inhibitors, 654
Cathepsin D
  combinatorial docking studies, 318
  non-peptide inhibitors, 227
Cathepsin K
  transition state analog inhibitors, 654–655, 656
Cation-P interactions, 286, 313
  enzyme inhibitors, 724–725
CATS descriptors, 192
CAVEAT, 111,113
CAVITY, 106–107,108
CBS reduction, 814
cDNA clone libraries, 341–342
cDNA microarray chips, 344–345
Cefaclor, 872
Cefadroxil, 872
Cefetamet pivoxil, 849
Cefozopran, 849
Cefpimizole, 849
Cefsulodin, 849
Ceftazidime, 872,873
Ceftizoxime, 872,873
Ceftriaxone, 872,873
Cefuroxime, 872,873
Cell-based partitioning methods, 203
CellCept
  structure-based design, 446–447
Central Library, 378,387
Central nervous system (CNS) drugs, See CNS drugs
Cephacetrile, 871,874
Cephalexin, 871–872
Cephaloglycin, 871–872
Cephaloridine, 871,872
Cephalosporin C, 870–871, 874
Cephalosporins, 717,870–871
  preventing bacterial degradation, 718
Cephalosporium acremonium, 870
Cephalothin, 871,874
Cephamandole, 872,873
Cephapririn, 871, 874
Cephradine, 872
Cerivastatin, 880
Cetirizine, 783
Cetirizine dihydrochloride
  chromatographic separation, 790–791
cGMP
  molecular property visualization, 137

CGS 27023
structure-based design, 444, 446
Chain branching alteration analogs, 699–704
Chapman databases, 387
Charge-charge interactions, 82
Charge-coupled devices (CCDs)
for electron cryomicroscopy, 623
for X-ray crystallography, 474
Charge-dipole interactions, 82
Charge parameterization, 101–102
Charge state determination
NMR spectroscopy for, 526
Charge transfer energy, 173
CHARMM, 298,299,307–308
in molecular modeling, 118, 126
CheD, 387
ChemBase, 362
CHEMCATS, 385
CHEMDBS3D, 260,363
ChemDraw, 362
ChemEnlighten, 387
ChemExplorer, 384
ChemFinder for Word, 384,388
ChemFolder, 388
Chemical Abstracts (CAS) registry file, 50
Chemical Abstracts Service databases, 254,361,385
Chemical business rules, 378, 403
Chemical information computing systems, 357–363
chemical property estimation systems, 388–390
chemical representation, 363-373
databases, 384-388
data warehouses and data marts, 390–393, 402–403
future developments, 393–397
glossary of terms used, 397–412
registering chemical information, 377–379
searching chemical structures1 reactions, 379–384
storing chemical information, 373–377
Chemical information management databases, 384
Chemical information management systems, 384
Chemical libraries, See Libraries
Chemical Products Index, 391-392
Chemical property estimation systems, 388390
Chemical reactions, 366
searching, 379–384
Chemical representation, 363–373
Chemical shift, in NMR, 511, 512
changes on binding, 536–537
perturbations as aid in NMR screening, 562–568
Chemical-shift mapping, in NMR, 543–545
Chemical similarity, 382
Chemical space, 244, 383,400
exploring with molecular similarity/diversity methods, 188, 191
reduction by virtual screening, 244–245
Chemical Structure Association, 360
Chemical structures
file conversion, 372-373
searching, 379–384
Chemical suppliers searching, 384
CHEM-INFO, 360
ChemInform, 386
Cheminformatics, 359,400
Cheminformatics Glossary, 360
ChemPort program, 385
Chemscape, 387
ChemScore
consensus scoring, 266
empirical scoring, 310
ChemSpace, 199
ChemText, 362
ChemWindow, 388
Chem-X, 60, 111
ChemX/ChemDiverse
3D pharmacophores, 195–196, 206
optimization approach, 217
and property-based design, 234
Cherry picking, combinatorial libraries, 216–217,237
Chesire, 378,387
Chicken liver DHFR, QSAR inhibition studies, 31–32
Chilies, capsaicin in, 854
Chime, 369,371,387
Chiral auxiliary, 810–813
Chiral catalysts, 814–820
Chiral centers, 783–785
Chiral derivatizing agents, 788
Chiral flags, 365,366
Chirality, 781–787,820–821
asymmetric synthesis, 804–820
chromatographic separations, 787–793
classical resolution, 793–799
enzyme-mediated asymmetric synthesis, 804–807
nonclassical resolution, 799–804
Chiral pool, 807–810
Chiral reagent, 813–814
Chiral stationary phase, 787–788,790–791
Chlopromazine, 692
Chloramphenicol, 870
molecular modeling, 150
4-Chloro-1,3-benzenediol
allergenicity prediction, 834
Chloromethyl ketones
protease inhibitors, 761–762
p-Chlorophenylalanine
classical resolution by crystallization, 798–799, 800
Chloroquine, 889,890
Chlortetracycline, 870
Cholchicine
toxicological profile prediction, 841,842
Cholecystokinin, 855
X-ray crystallographic studies, 484
Chorismate mutase inhibitors
transition state analogs, 753–754
Chromatographic separation of chiral molecules, 787–793
Chromobacterium violactum, 873
Chromosomes
in genetic algorithms, 87
Chymotrypsin inhibitors
affinity labels, 761, 762
molecular modeling, 118
QSAR studies, 5, 35–36
CICLOPS, 223
Cilazapril
asymmetric synthesis, 807, 809
Cilofungin, 877
Cinchona bark, quinine from, 888

CIP (Cahn-Ingold-Prelog) stereochemistry, 365,400
Cisplatin
  vindesine with, 860
cis/trans stereochemistry, 399
Clarithromycin, 849,874, 875–876
Classical resolution, of chiral molecules, 793–799
Clavulanic acid, 718,869,870
Cleaning and transforming data, 400
Clenbuterol
  chromatographic separation, 787,788
Client-server architecture, 400–401
Clipping, 378,401
Clique search techniques, 262
CLOB (Character Large Object) data type, 401
Clofibric acid
  antisickling agent, 421, 422
CLOGP, 18,389
Clog P, 17–18, 36
Cloning, 127
  cDNA clone libraries, 341–342
Clotrimazole, 717
Clustering methods, 379,401
  for combinatorial library design, 220
  in molecular modeling, 90–91
  with molecular similarity/diversity methods, 205
CML (Chemical Markup Language), 371–372, 401, 405, 412
CNS drugs
  complementarity, 134
  natural products as leads, 849–856
  pharmacophore point filters, 250
  polar surface area, 245
CNS program, 478
Coagulation factor 2
  X-ray crystallographic studies, 484–485
Coagulation factor 7
  X-ray crystallographic studies, 485
Coagulation factor **7a**
  X-ray crystallographic studies, 485–486
Coagulation factor 9
  X-ray crystallographic studies, 486
Coagulation factor 10
  X-ray crystallographic studies, 484
COBRA, 255
R-Cocaine
  dopamine transporter inhibitor, 268
Codeine, 849,850
Coformycin, 750–752
Cognex
  structure-based design, 449
Colforsin daropate, 849
Collagenase
  NMR binding studies, 555, 556
  target of structure-based drug design, 443
CombiBUILD, 227
CombiChem Package, 386
CombiDOCK, 217,227
  combinatorial docking, 318
CombiLibMaker, 378,387
Combinatorial chemistry, 283, 358,591–592
  defined, 401
  and molecular modeling, 155
  and natural product screening, 848
Combinatorial chemistry databases, 387
Combinatorial docking, 317318
Combinatorial libraries, 214
  comparisons, 221–223
  design for molecular similarity methods, 190,214–228
  encoding and identification with mass spectrometry, 596–597
  integration, 224–225
  LC-MS purification, 592–594
  optimization, 217–221
  peptidomimetics, 657
  screening for ligands to two receptors simultaneously, 601–602
  structure-based design, 225–228
  structure/purity confirmation with mass spectrometry, 594–596
  with virtual screening, 317
S,S-Combretadioxolane, 816, 819
Combretastatin A-4,816,819
CoMFA, See Comparative molecular field analysis
Compactin, 744,879
Comparative binding energy analysis (COMBINE), 53
  and docking methods, 304–305
Comparative molecular field analysis (CoMFA), 53–54
  assessment of predictability, 151–153
  3D, 58–60
  and docking methods, 304
  field mapping, 107
  molecular field descriptors, 56–57
  and molecular modeling, 138, 147
Comparative quantitative structure-activity relationships
  database development, 39
  database mining for models, 39–41
Competitive inhibitors, 728–729
Complementarity, 134
Comprehensive Medicinal Chemistry database, 379, 386
Computational Chemistry List, 360
Computational protein-ligand docking techniques, 262–264
Computing technologies, 334–335, 337. See also Chemical information computing systems
COMSiA, 53, 60
CONCORD, 363,366,387,401
  3D coordinate generation, 267
  3D descriptors, 55, 110
  virtual screening application, 254
Concordance, 390,401
Conformational analysis
  in molecular modeling, 87, 93–94
  NMR spectroscopy for, 525–526
  and systematic search, 89–93
Conformational clustering, 92–93
Conformational flexibility, 288
Conformationally restricted analogs, 694–699
Conformationally restricted peptides, 636–643
Conformational mimicry, 140–142

Conformational mimicry index, 142
Conglomerate racemates, 799–800,801,802–803
Connection tables, 365–368,371, 401
  file conversion, 372373
  ISIS database, 376
Connectivity, See Molecular connectivity
ω-Conotoxins
  lead for drugs, 851–852
  NMR spectroscopy, 518–523
ConQuest search program, 387
Conscore constraint score, 218
Consensus scoring, 265–266, 291,319–320
  and molecular modeling, 117–118
Consistent force fields, 102
Constrained minimization, 143–144
Contact matrix, 125–127
Contignasterol, 886
CONTRAST, 361
Conus magus, conotoxins from, 851
Convertases
  homology modeling, 123
CONVERTER, 366,402
CoQSAR, See Comparative quantitative structure-activity relationships
CORINA, 366,402
  3D coordinate generation, 267
  3D descriptors, 55
  virtual screening application, 254
Cosine coefficient, 68
COSMIC force field, 80
Coulomb's law, 80, 82, 285
  and dielectric problem, 83
Coumarin, 882
Counting schemes
  in druglikeness screening, 245–246
Coupling constants, in NMR, 511,512
  changes on binding, 536–537
  for conformational analysis, 525
COUSIN, 361,373,387
  and combinatorial library integration, 224
Covalent bonds, 6,170
Covalently binding enzyme inhibitors, 720, 754–756
  inactivation of, 756–760
Cox-1 inhibitors, 718
  X-ray crystallographic studies, 486
COX-2 inhibitors, 718
  mass-spectrometric binding assay screening, 604
  seeding experiments, 319
  X-ray crystallographic studies, 486
CP-96,345, 670,672
C-QSAR database, 39
Crambin
  molecular modeling, 124
Crixivan
  structure-based design, 438–439
CROSS-BOW, 361
Crossfire Beilstein, 385
Cross-linked enzyme crystals, 804
Crosslinking agents, 424–425
Cross validation, 57, 64
Cryoprobes
  in NMR screening, 577
  in NMR spectroscopy, 515
Cryptotheca *cripta,* 867
Crystallization
  for asymmetric transformation of enantiomers, 798–799
  for enhancing chromatographic separation of enantiomers, 792–793
  in nonclassical resolution, 799–804
CScore, 117
Curare
  lead for drugs, 856–858
Cyclic lactams
  conformationally restricted peptidomimetics, 640–642
Cyclic protease inhibitors, 636
Cyclin-dependent kinase 2 (CDK2)
  H717 inhibitor pharmacophore, 253
Cyclo(Gly$_6$)
  genetic algorithm exploration of conformational space, 88
Cycloheptadecane
  potential smoothing study, 86
Cyclooxygenase 1/2 inhibitors, See COX-1 inhibitors; COX-2 inhibitors
Cyclophilin, 552
D-Cycloserine, 717, 719
Cyclosporin, 848
  molecular modeling, 106
  NMR spectroscopic binding studies, 539
Cyclosporin A
  binding to FKBP, 552–553
γ-Cystathionase inhibitors, 719–720
Cysteine
  chemical modification reagents, 755
Cysteine peptidase inhibitors
  transition state analogs, 652–655
Cysteine protease inhibitors
  affinity labels, 762
Cytochrome P450
  homology modeling, 123
Cytochrome P450 reductase
  X-ray crystallographic studies, 486
Cytosine arabinoside, 717, 867–868

D2163, 804, 806
Daemon, 392,402
Daffodils, drugs derived from, 892
Dalfopristin, 876–877
Spiro-DAMP, 696
4-DAMP
  semirigid analogs, 695–696
Daptomycin, 848
DARWIN, 299
  explicit water molecules, 303
Databases
  for bioinformatics, 345349
  cDNA microarray chips, 345
  chemical information management, 384
  commercial systems for drug-sized molecules, 384387
  comparative QSAR, 39–41
  comparing expressed sequence tags with, 342
  history of, 360–363
  knowledge discovery in, 393395
  natural products, 387,597
  for pharmacophore screening, 254–255
  proprietary and academic, 387–388
  sequence and 3D structure, 387
  storing chemical information in, 373–377

for X-ray crystallography, 478–479
Database tier, 393,403,407
Data cartridges, 395,402
Data compression, 402
Data dictionary table, 375
Data marts, **391–393, 402**
Data mining, 402,410,411,412
future prospects, 394–395
with QSAR, 66–67
Data warehouses, 390–393, 402–403
Dative bonds, 170,365
Daunomycin
thermodynamics of binding to DNA, 183
DayCart, 386
DayCGI, 386
Daylight Chemical Information Systems databases
descriptors, 192
in virtual screening, 254
10-Deacetylbaccatin11,803
Decamethonium, 58
fragment analogs, 708–710
lead for drugs, 856–858
Deceptive fitness functions, 88
Decision support systems, 403
Decision tree approach, **247–248**
Deconvolution, 401
Deduplication, 378,403
Dehydroalantolactone
allergenicity prediction, 836
Demexiptiline, 692–693
DENDRAL, 393
De *novo* design, 113
***(R)*-Deoxycoformycin**, 750–752
***(S)*-Deoxycoformycin**, 751
DEREK, 246
Derwent Information databases, 386
Derwent Selection database, 386
Derwent World Drug Index (**WDI**), 379, 386, 387
Derwent World Patents Index (**WPI**), 386
10-Desacetylbaccatin 111,863
Descriptor pharmacophores, **60–63**
Design in Receptor (**DiR**) approach, 236
DHFR, See Dihydrofolate **reductase**
Diamino, 5Y, 6-Z-quinazolines
QSAR studies of DHFR inhibition, 34–35
Diastereomers, 784
chromatographic separation, 788
Dice coefficient, 68
Dicoumarol, 882
Dictionary of Natural Products, 597
Dideoxyinosine, 717
Dielectric problem, 83–84
Dienestrol, 706–707
Diethylstilbestrol
stereoisomer analogs, 706–707
Diffusion-filtered NMR screening, 570–571
a-Difluoromethylornithine, 717
Digital Northern, 342
Dihydroartemisinin, 887
Dihydrofolate reductase inhibitors, 545, 717
chemical-shift mapping of binding, 545
comparative molecular field analysis, 153
genetic algorithm study of active site, 89
genetic algorithm study of docking, 88–89
interaction with **methotrexate**, 120
interaction with **trimethoprim**, 151,183
interaction with trimetrexate, 531,557459
mass-spectrometric binding assay screening, 604
molecular modeling, 114, 115, 116,147,151
QSAR studies, 5
QSAR studies of inhibition by diamino, 5Y, 6-Z-quinazolines, 34-35
QSAR studies of inhibition by diamino-5X-benzyl pyrimidines, 39
QSAR studies of inhibition by **triazines**, 31–33
target of structure-based drug design, 425–426
volume mapping, 140
X-ray crystallographic studies, 486
Dihydromuscimol, 690
Dihydroorotase
transition state **analogs**, 752
Dihydroorotate dehydrogenase inhibitors
X-ray crystallographic studies, 486
Dihydropteroate synthetase inhibitors, 717
X-ray crystallographic studies, 486
1,4-Dihydropyridines
chromatographic separation, 788,789
Dihydroquinine, 889
Dihydrotestosterone, 36, 768
Diller-Merz rapid docking approach, 292,295
assessment, 303
combinatorial docking, 317
Diltiazem
nonclassical resolution, 803, 805
Dimension tables, 390,403
***N*,*N*-Dimethyldopamine**
alkyl chain homologation analogs, 701
bioisosteric analogs, 690, 692
semirigid analogs, 695
$\Delta_{6a,10a}$-DimethylheptylTHC, 852
Dimethyl sulfoxide (**DMSO**)
force field models for, 176
Dimethyltubocurarine, 857
Diphenylmethane, 231
privileged structures, 252
2,3-Diphosphoglycerate (2,3-DPG), 104,421
2,3-Diphosphoglycerate (2,3-DPG) analogs, 103, 104
Dipolar electrostatic forces, 172
Dipole-dipole interactions, **6, 82**
Dipole-induced dipole interactions, 173
Directed tweak algorithm, 260
Directionality, 140
DISCO, **58, 60, 256**
and molecular modeling, 147
Discodermolide
genotoxicity prediction, 843
Disintegrins, 652
Disoxaril
structure-based design, 454–455
Dispersive interactions, 82, 174. See also van der **Waals** forces
Dissimilarity approaches, 189–190,206–208
Dissociation constant, 286
Distamycin
binding perturbations, 544

Distance geometry methods
in molecular modeling, 126, 142,147
in QSAR, 60
in virtual screening, 263
Distance geometry QSAR technique, 53
Distance matrix, 135
Distance measures
molecular modeling, 135–137
molecular similarity/diversity methods, 201–202
Distance range matrix, 135–136
Dithromycin, 875
DiverseSolutions, 387
for molecular similarity/diversity methods, 193–194, 203–204
Diversity analysis, 358
Diversity methods, See Molecular similarityldiversity methods
Diversity-property derived (DPD) method, 201,203
Dixon plots, 731–732
D,L descriptors, for chiral molecules, 783
DMB-323
NMR binding studies with HIV protease, 560–562
DMHB
structure-based design, 424
DMP 450,659
structure-based design, 438–439
DNA
molecular modeling, 154
NMR structural determination, 535
noncovalent bonds in, 170
supercoiling modeling, 95
synthesis inhibition by phenols, 40
DNA-binding drugs
chemical-shift mapping of binding to, 544–545
molecular modeling, 116
NMR spectroscopy, 547–552
thermodynamics of binding, 183
DNA gyrase inhibitors
novel lead identification, 321
DNA helicase pcra
X-ray crystallographic studies, 487
DNA polymerase inhibitors, 342, 717
DNA topoisomerase 1
X-ray crystallographic studies, 487
Docetaxel, 849,863
DOCK
anchor and grow algorithm, 296
assessment, 303,304
combinatorial docking, 318
consensus scoring, 266
empirical scoring, 310
force field-based scoring, 308
force-field scoring, 264
geometric/combinatorial search, 295
ligand handling, 293
molecular modeling, 112, 113, 115,116
molecular modeling of small cavity, 106, 107
penalty terms, 313
performance in structure prediction, 314
protein and receptor modeling, 267
protein flexibility, 301
receptor representation in, 291
rigid docking, 262–263
sampling/scoring methods used, 261
seeding experiments, 319
with site-based pharmacophores, 236
DOCK4.0
PMF scoring, 265
weak inhibitors, 319
DockCrunch project, 317
Docking methods. See also Scoring functions; various docking programs; Virtual screening
assessment, 303-304
basic concepts, 289–290
combinatorial, 317–318
flexible ligands, 293–294,322
and homology modeling, 305–306
and molecular modeling, 113–118
and molecular size, 312313
NOE docking in NMR, 545–546
penalty terms, 313
protein flexibility, 300–302, 322
protein-ligand docking software, 261
and QSAR, 304–305
searching configuration and conformation space, 294–300
seeding experiments, 318–319
special aspects, 300–306
in structure-based virtual screening, 260–267
as virtual screening tool, 266–267
water's role, 302–303, 313–314
Docking problem, 289
DockIT, 261
DockVision, 261
Dolabella auricularia, 868
Dolastatin-10, 868,869
DoMCoSAR approach, 305
Donepezil
structure-based design, 449
L-Dopa, 785
analogs, 690
Dopamine
semirigid analogs, 697
Dopamine-transporter inhibitors
pharmacophore model, 256, 258
virtual screening, 267–269, 270
D-Optimal designs, 65–66
Dose-response curves, 8
Dothiepin, 692–693
Doxepin, 692–693
DragHome method, 305
DRAGON, 388-389
DREAM++, 318
Drill-down, 391,403
Dronabinol, 849
Drug databases, 385–386. See also Databases
Drug Data Report, 379,386
Drug development, 509-510
serial design costs, 359
Druglikeness screening. See also Lipinski's "rule of 5"
molecular similarity/diversity methods, 191
similarity searching, 383
virtual screening, 245–250
Drug-receptor complexes, 170–179
low energy state of, 5
Drug resistance
antibiotic resistant pathogens, 770

essential pathways versus single enzyme inhibitor, 495
DrugScore function, 311,312
assessment. 303
performance in structure prediction, 314
seeding experiments, 319
in virtual screening, 315
Drug screening, See Screening
Drug-target binding forces, 170–171
association thermodynamics, 170–171,177–179
energy components for intermolecular noncovalent interactions, 171–174
example drug-receptor interactions, 181–183
free energy calculation, 180–181
molecular mechanics force fields, 174–177
Drug targets
and bioinformatics, 351–352
estimated number of, 50
x-ray crystallography of published structures, 482–493
DYLOMMS, 107

E. Coli
mutagenicity prediction, 829
Eadie-Hofstee plot, 727, 729, 731
ECEPP force field, 118
Echinocandins, 877–878
Ecteinascidia turbinata, 868
Ecteinascidin-743, 848, 867–868
ECTL (Extracting, Cleaning, Transforming, and Loading) data, 377–379,403
Edman sequencing, 518
Edrophonium, 58
Efaproxaril (RSR-13), 422
Eflornithine, 768, 769
Eigenvector following method, 292,301
Einstein-Sutherland equation, 24
Elan, 387
Electron cryomicroscopy, 611–628
image processing and 3D reconstruction, 624–628
image selection and preprocessing, 623–624
three-dimensional, 615–616
Electron-donating substituents, 12–15
growth inhibition by, 41
Electronic parameters in QSAR, 11–15, 50
Electron lenses, 612
Electron probability distribution, 101
Electron-topological matrix of congruence, 147
Electron-withdrawing substituents, 11–15
growth inhibition by, 41
Electrospray FTICR mass spectrometry, 601–603
Electrostatic interactions, 171–172,285
charge parameterization, 101–102
and docking scoring, 308
enzyme inhibitors, 721, 723
long range, 177
molecular modeling, 81–85, 108–110,140
and molecular property visualization, 137
and QSAR, 6–7, 52
Electrotopological indices, 4
Elimination algorithms, 207
EMBL Nucleotide Sequence Database, 335
Embryo tail defects, 40
EMD 122946,676
Empirical scoring, 264, 307, 308–310
Enalapril, 650,747,881
asymmetric synthesis, 807, 809
conformationally restricted peptidomimetics, 640–641
Enalaprilat, 650, 747
conformationally restricted peptidomimetics, 640–641
Enantiomeric excess, 784
enrichment by crystallization, 800–802
Enantiomers, 365, 366. See also Chirality
with agonist-antagonist properties at same receptor, 705
chromatographic separations, 787–793
defined, 783–785
Enantioselective metabolism, 786–787
Enantioselectivity, 784
Encoding
and genetic algorithm, 88
natural products with mass spectrometry, 596–597
Encryption, 403
Endorphins, 634, 850–851
model receptor site, 149
Endothelin
antagonists, 211, 672–674, 675,676
conformationally restricted peptidomimetics, 637, 639
NMR spectroscopy, 523–524, 526–527
ENERGI approach, 127
Energy driven/stochastic search strategies, 292,296–2300
Energy of association, 177
English yew, paclitaxel from, 861–862
Enkephalins, 634,850–851
conformationally restricted peptidomimetics, 129, 637, 639
model receptor site, 149
Ensemble, 94
Enthalpy of association
drug-receptor complexes, 170–171
Entoviruses
target of structure-based drug design, 454–456
Entrainment, 802
Entropy, 94
Entropy of association
drug-receptor complexes, 170–171
Enumerated structure, 368
Enumeration, 401,403
Enzyme-induced inactivators, 756
Enzyme-inhibitor complexes, 721–722
Enzyme inhibitors, 715–720. See also specific Enzymes
affinity labels, 756–759, 760–764
design of covalently binding, 720, 754–756
design of noncovalently binding, 720–754
examples used in disease treatment, 717
ground-state analogs, 720, 740–741
inactivation of covalently binding, 756–760
mechanism-based, 759–760, 764–771
multisubstrate analogs, 720, 741–748

Enzyme inhibitors (Continued)
pseudoirreversible, 771-774
rapid, reversible, 720, 728-734
slow-, tight-, and slow-tight-binding, 720, 734-740, 749
transition-state analogs, 720, 748-754
Enzyme-mediated asymmetric synthesis, 804-807
Enzymes
as drug targets, 5
kinetics, 725-728
pathways and inhibitor design, 495
and structural genomics, 352
Ephedra, 885
Ephedrine, 884-886
(-)-Epibatidine, 819-820, 821
Epothilone A, 864
toxicological profile prediction, 838-839
Epothilone B, 864-865
Epothilone D, 865
Epoxides
filtering from virtual screens, 246
Equivalence class, 403
Erythro-9-(2-hydroxy-3-nonyl) (EHNA)
high-affinity adenosine deaminase ligand, 604
Erythromycin, 870, 871
Erythromycin macrolides, 874-876
Erythro- prefix, 784
Erythrose
enantiomers, 784
E_s constant (Taft), 23-24
E-selectin
NMR screening binding studies, 572
E-State index, 26, 54
Esters
pharmacophore points, 249
Estradiol, 706, 771
Estrogen receptor l a
X-ray crystallographic studies, 487
Estrogen receptors
mass-spectrometric binding assay screening, 604
Ethacrynic acid
antisickling agent, 421
Ethidium bromide
thermodynamics of binding to DNA, 183
Etodolac
classical resolution, 796-797
Etoposide, 717, 867
Etorphine, 851
Euclidean distance, 68, 202
EUDOC
assessment, 303
ligand handling, 293
European Bioinformatics Institute (EBI), 335
sequence databases, 387
Everolimus, 849
Evolutionary algorithms, 299
with QSAR, 53–54, 61
Exact match search, 378, 379-381, 403
Exchange repulsion energy, 172-173
Exemestane, 770, 771
Exhaustive mapping, 398
Expert Protein Analysis System, 335
Expressed sequence tags, 338
expression level significance, 342-344
profiling, 341-342
Expression analysis/profiling, 334
genome-wide, 344345
for target discovery, 340-345
Extended stereochemistry, 365, 404
External registry number, 379, 404
Extrathermodynamic relationship, 26
E,Z system, 365, 399

Factorial designs, 65-66
Factor Xa inhibitors, 103, 738
3D pharmacophores, 199
non-peptide peptidomimetics, 662.665
site-based pharmacophores, 235-236
target of structure-based drug design, 442
Fact tables, 390, 401, 404
Failed Reactions database, 385
Families, 93
Family competition evolutionary algorithm, 299
FASTA, 347
Fast ion bombardment, 586, 587
Fastsearch index, 376377, 399, 404
FBSS, 202
FeatureTrees, 316, 321
Fibonacci search method, 11
Fibrinogen
virtual screening studies, 212-213
Field-based descriptors, 201
Field effects, 140
Field mapping, 107
Fields, 404
Filtercascade, 267
Filters, for searching, 315-316, 376, 380, 392, 404
Finasteride, 717, 768-770
Fingerprint Generation Pack, 388
Fingerprints, 376, 378, 399, 404
molecular similarity methods, 188
FIRM, 67
Fitness functions, 87-88
FK506
binding to FKBP, 552–555
NMR spectroscopic binding studies, 539
FK506 binding protein inhibitors, 552-555
de novo design, 113
flexible docking studies, 265
hydrogen bonding in, 288
target of NMR screening studies, 565–566, 571
weak inhibitor screening, 319
X-ray crystallographic studies; 487
Flat database storage, 362–363, 404
Flat file storage, 360-362, 404
Flecainide
enantiomers, 786
FlexE, 301
Flexibase/FLOG, 263
Flexible ligands
in docking methods, 293-294, 322
and geometric/combinatorial search, 295
in virtual screening, 263-264
Flexmatch index, 376
Flexmatch search, 404
FlexS, 316
novel lead identification, 320, 321
FlexX
assessment, 303, 304
consensus scoring, 266, 320
empirical scoring, 264, 310
explicit water molecules, 302

hydrogen bonding, 319
incremental construction, 295–296
molecular modeling, 115
novel lead identification, 320
performance in structure prediction, 314
protein and receptor modeling, 267
receptor representation in, 291
sampling/scoring methods used, 261
seeding experiments, 319
FlexX^c extension, 318
Flickering cluster model, of hydrophobic interactions, 15
Flo, 256
Flobufen, 41–42, 42
FLOG
explicit water molecules, 303
ligand handling, 293
and molecular size, 312313
seeding experiments, 318
Flunet
structure-based design, 451
Fluorescence spectroscopy, 592
4-Fluorobenzenesulfonamide
binding to carbonic anhydrase, 538
5'-p-Fluorosulfonylbenzoyl adenosine (5'-FSBA), 763–764
5-Fluorouracil, 717, 718
Flurbiprofen, 763
Fluvastatin, 744,879–880
FOCUS-2D method, 68–69
Fold compatibility methods, 353
Fold patterns
limited number of, 353
Follicle stimulating hormone
X-ray crystallographic studies, 488
Force fields
drug-target binding forces, 170–183
molecular modeling, 79–81
parameter derivation, 102–103
Force-field scoring, 264, 306–308
Formestane, 770, 771
Formula table, 376
FOUNDATION, 112–113
Fourier transform ion cyclotron resonance (FTICR) mass spectrometry, 585,601–603
4-Point pharmacophores, 408
molecular similarity methods, 189,196–198,205
privileged, 231
virtual screening, 210
FPL-67047
structure-based design, 453
Fractional factorial designs, 66
Fragment analogs, 707–710
Fragment-based ligand docking, 294
FRED
ligand handling, 293
sampling/scoring methods used, 261
Free energy of association, 286
calculating, 180–181
drug-receptor complexes, 5, 170–171
enzyme-inhibitor complexes, 722
Free energy perturbation, 307, 308
Free-Wilson approach, in QSAR, 4, 29–30
Frontal affinity chromatography-mass spectrometry, 601
5-FSA
structure-based design, 424
FTDOCK, 115
Ftrees-FS algorithm, 221
Fujita-Ban equation, 4
Fujita-Nishioka analysis, 13
Functional genomics, 338–340
Functional group filters
in druglikeness screening, 246–247
Functional mimetics (peptidomimetics), 636
Fungal natural products, 848, 893
Fungal squalene epoxidase inhibitors, 717
Fungal sterol 14α-demethylase inhibitors, 717
Fuzzy bipolar pharmacophore autocorrelograms, 197
Fuzzy clustering technique
with molecular similarity/diversity methods, 205
Fuzzy distance, 57–58
Fuzzy searches, 376

G-4120,663
GABA, *See* γ-Aminobutyric acid
GABA aminotransferase (GABA-T) inhibitors, 718, 766–767
X-ray crystallographic studies, 488
β-D-Galactoside
saturation transfer difference in binding to agglutin I, 569
Galantamine (galanthamine), 848,849,892–893
nonclassical resolution, 802, 803
GALOPED, 218
Gambler
consensus scoring, 266
flexible ligands, 263
seeding experiments, 319
Gas chromatography, 592
for enantiomer separation, 787
Gas chromatography-mass spectrometry (GC-MS), 585–586
GASP (Genetic Algorithm Similarity Program), 256
in molecular modeling, 147
Gas phase association, 177, 178
G-CSF 3
X-ray crystallographic studies, 488
Gelatinase
NMR binding studies, 555
Gel permeation chromatography-mass spectrometry, 599
GenBank, 335
growth of, 339
X-ray crystallography application, 481
GeneChips, 344
Gene expression, 351. See also Expressed sequence tags; Expression analysis/profiling
Gene family approaches, 188, 244
subset selection, 190–191
Gene family databases, 347–349
Gene nomenclature, 337
Gene Ontology project, 337
Generic structures, 367, 368, 404–405
Geneseq database, 346
Genetic algorithms
and combinatorial library design, 217,218
with docking methods, 292, 298–299

Genetic algorithms (Continued)
with FOCUS-2D method, 68–69
inverse folding and threading, 124–125
Lamarckian, 299
in molecular modeling, 87–89, 117
with QSAR, 53, 61
in virtual screening, 263
GeneTox, 829
Genie Control Language, 378
Genitoxants, 840
Genome annotation, 481,494
Genome-wide expression analysis, 344345
Genomics, See Functional genomics; Phylogenomics; Structural genomics
GEOCORE, 124
Geometric atom-pair descriptors, 210
Geometric/combinatorial search strategies, 292,295
Geometric hashing, 262
Geometric isomer analogs, 704–707
Ghost membranes
EPR signal changes by ROH, 27
Ghrelin, 671, 674
GHRP-6,671,674
Gibbs-Helmholtz equation, 286
Gigabyte, 405
GLIDE
sampling/scoring methods used, 261
Global stereochemistry, 398
Glucocorticoid receptor
X-ray crystallographic studies, 488
Glucose, 784
Glutamate dehydrogenase, 764
Glutamate NDMA agonists, 150
Glutamate NDMA antagonists, 150
Glutamate receptor 1
X-ray crystallographic studies, 488
Glutamic acid
chemical modification reagents, 755
nonclassical bioisostere analog, 694
rigid analogs, 699
Glutamine-PRPP amidotransferase inhibitors, 717
Glutathione peroxidase
X-ray crystallographic studies, 488
Glycinamide ribonucleotide formyltransferase inhibitors, 742–743
target of structure-based drug design, 429–432
Glycophorin A
potential smoothing study of TM helix dimer, 86
Glycoprotein IIb/IIIa (GpIIb/IIIa) inhibitors
non-peptide peptidomimetics, 662–665
template mimetics, 129, 643, 645
Glycopyrrolate
stereoisomers, 784–785
Gmelin database, 386
GOLD
assessment, 303, 304
empirical scoring, 309
flexible ligands, 263
genetic algorithm, 299
protein flexibility, 300
sampling/scoring methods used, 261
GOLEM, 67
GOLPE, 54, 60
GPCR libraries
3D pharmacophore fingerprints for, 205
GPCR-likeness, 251,252
GPCRs (G-protein-coupledreceptors), 668
focused screening libraries targeting, 209,250
homology modeling, 123, 150
molecular modeling, 122
peptidomimetics, 644, 677
7-transmembrane, 229–234
GRAB-peptidomimetic (Group-Replacement Assisted Binding), 636,658–659,677
GRAMM (Global Range Molecular Matching), 115
Granulocyte-macrophage CSF
X-ray crystallographic studies, 488
Graphical representation, 371
Graph isomorphism problem, 380,405
GREEN
force-field scoring, 264
GRID, 58,315
3D pharmacophores, 198
empirical scoring, 309
explicit water molecules, 303
hydrogen bonding, 107
and molecular modeling, 138
Gridding and Partitioning (GaP) approach, 199,200
GRID/GOLPE analysis, 304–305
Grid tyranny, 91, 144
GRIND, 60
Groove-binding ligands, 5
Ground-state analog enzyme inhibitors, 720, 740–741
Growth hormone receptor
X-ray crystallographic studies, 488
Growth hormone secretagogues, 671–672,675
GS 4071
structure-based design, 452
Guanidine
pharmacophore points, 249
Gusperimus, 849

Hall databases, 387
Haloperidol
HIV protease inhibitor, 111, 112
Halopyrimidines
filtering from virtual screens, 246
Hammett constants, 11, 50
Hammett equation, 12, 13, 26, 50
Hamming distance, 202
Hammond postulate, 748
Hanes-Woolf plot, 727, 729, 731
Hansch approach, to QSAR, 26–27, 30
Hansch-Fujita-Ban analysis, 31
Hansch parabolic equation, 3
Hansch-type parameters, 54
HARPick program, 218,221
Hash code, 376,380,405
and combinatorial library design, 223
molecular fragment based, 54
Hemicholinium
interatomic distance analogs, 710–711
Hemoglobin
molecular modeling of crystal structure, 105, 107
target of structure-based drug design, 419–425
Hepatocyte growth factor activator inhibitor 1
mariptase inhibitor, 269,271

Heroin, 849-850
HE-State index, 26
Heterochiral molecules, 782
Heteronuclear multiple bond correlation spectroscopy
  natural products, 518
Heteronuclear single quantum correlation spectroscopy, 512
Hexestrol, 707
Hierarchical clustering, 220, 401, 405
  with molecular similarity/diversity methods, 205
High density oligonucleotide arrays, 344
High performance liquid chromatography (HPLC), 586-589
  for combinatorial library screening, 592-596, 598, 599, 607
  fast, 596
  for hydrophobicity determination, 16–17, 23
  for separation of chiral molecules, 783, 788-792
High-throughput chemistry, 358, 405
  chemical libraries for, 367
  and natural product screening, 848
High Throughput Crystallography Consortium, 418
High-throughput screening, 283
  mass spectrometry applications, 591, 592-596
  and molecular modeling, 155
  molecular similarity/diversity methods, 191
  raw data points obtained by companies, 50
  with virtual screening, 316
  X-ray crystallography application, 472
HIN file format, 369
HINT descriptors, 56
Hint!-LogP, 389
HipHop, 60, 256
Histamine antagonists
  molecular modeling, 143
Histidine
  chemical modification reagents, 755
Hit list, 380, 405, 411
HIV protease inhibitors, 717
  binding-site molecular models, 130
  comparative molecular field analysis, 153
  consensus scoring study, 266
  3D CoMFA, 59
  de *novo* design, 113
  force field-based scoring study, 307
  homology modeling, 123
  knowledge-based scoring study, 311
  molecular modeling, 103-104, 105, 108, 109, 111, 117, 120, 122
  NMR binding studies, 533, 559-562
  non-peptide peptidomimetics, 659-660
  novel lead identification by virtual screening, 320
  seeding experiments, 318–319
  target of structure-based drug design, 433-442
  transition state analogs, 647-649
  and water, 302
HIV reverse transcriptase inhibitors, 717
  X-ray crystallographic studies, 488-489
H^+,K^+-ATPase inhibitors, 718
HKL suite, 478
Hoechst 33258
  binding to DNA, 544, 547-552
Homochiral molecules, 782
HOMO (Highest Occupied Molecular Orbital) energy, 11, 14, 54
Homology, 348
  and X-ray crystallography, 494
Homology modeling, 261–262
  and docking methods, 305306
  molecular modeling, 123
Homo *Sapiens*
  genome sequencing, 344
HQSAR, 4
HTML (HyperText Markup Language), 371, 405
HUGO Gene Nomenclature Committee, 337
Human Genome Database
  protein classes, 262
Human genome sequencing, 344
Human serum albumin, *See* Serum albumin
Hydrofinasteride, 768, 770
Hydrogen bonds, 285–286, 365
  acidic protons and π-systems, 313
  and empirical scoring, 309-310
  enzyme inhibitors, 722, 724
  hydrophobic interactions contrasted, 319
  molecular modeling, 81, 107-108
  and QSAR, 6
  and structure-based design, 409
Hydrolases
  target of structure-based drug design, 449-454
Hydrolysis
  enzyme-mediated asymmetric, 805-806
Hydrophobic bond, 15
Hydrophobic effect, 178, 182
Hydrophobic interactions, 50, 286, 287-288
  discovery of importance of, 3
  and empirical scoring, 310
  enzyme inhibitors, 724
  hydrogen bonding contrasted, 319
  molecular modeling, 85, 108-110
  and QSAR, 6, 7, 15–19, 23, 52
Hydrophobicity, 16-17
  determination by chromatography, 17–18, 23
(*S*)-3-Hydroxy-γ-butyrolactone, 808, 810
Hydroxychloroquine, 891
6*R*-Hydroxy-1,6-dihydropurine riboside, 752
Hydroxyethylurea, 153
R-(-)-11-Hydroxy-10-methylaporphine, 705
Hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitors, 718, 719, 744-746
(±)-3-(3-Hydroxyphenyl)-*N*-*n*-propylpiperidine (3-PPP), 704-705
D,L-3,5-Hydroxyvalerate, 745
HYPER, 727
HypoGen, 256
Hypothetical descriptor pharmacophore, 63

Iceberg model, of hydrophobic interactions, 15

ICM
affinity grids, 293
homology modeling, 305
ligand handling, 294
Monte Carlo minimization, 298
novel lead identification, 320
IC_{50} values, 731–732
QSAR, 8
ID3, 67
iDEA, 390
IDEALIZE, 255
Identification. *See* also Lead identification
combinatorial library compounds, mass spectrometry application, 596–597
mass spectrometry application, 594–596
Idoxuridine, 717
Ifosfamide, 783
Imines
filtering from virtual screens, 246
Iminobiotin
binding to avidin, 181, 182
Imipenem, 872–873,874
Imipramine
analogs, 692–693
Immobilized enzyme inhibitors, 720
Immunophilins
chemical-shift mapping of binding to, 545
FK506 binding to FKBP, 552–555
Importance sampling, 98
Incremental construction
in docking, 292, 295–296
in virtual screening, 262, 317–318
Indexes, 376–377,405
Indinavir, 648,659
structure-based design, 438–439,440,441
Indomethacin, 453
Inductor variables, 25–26
Influenza virus neuraminidase inhibitors, 717
InfoChem ChemReact/ChemSynth database, 386
InfoChem SpresiReact database, 386
Infrared spectroscopy, 592
Inhibitors. *See* also Enzyme inhibitors; specific inhibition targets: i.e., Dihydrofolate reductase inhibitors
finding weak by virtual screening, 319
not all are drugs, 408
structure of free, and structure-based design, 409
In-house databases, 387–388
Inosine monophosphate dehydrogenase
consensus scoring study, 266
seeding experiments, 318–319
target of structure-based drug design, 446–447
Inosine monophosphate dehydrogenase 2
X-ray crystallographic studies, 489
In silico screening, 191,244. *See* also Virtual screening
Insulin-like growth factor 1
X-ray crystallographic studies, 489
Insulin-like growth factor 2
X-ray crystallographic studies, 489
Insulin-like growth factor 1 receptor
X-ray crystallographic studies, 489
Integrin alphaM
X-ray crystallographic studies, 489
Interatomic distance variant analogs, 710–712
Intercellular adhesion molecule 1
X-ray crystallographic studies, 489
Interferon a 1
X-ray crystallographic studies, 490
Interferon γ
X-ray crystallographic studies, 490
Interleukin 1
X-ray crystallographic studies, 490
Interleukin 2
X-ray crystallographic studies, 490
Interleukin 3
X-ray crystallographic studies, 490
Interleukin 4
X-ray crystallographic studies, 490–491
Interleukin 5
X-ray crystallographic studies, 491
Interleukin 6
X-ray crystallographic studies, 491
Interleukin 8
X-ray crystallographic studies, 491
Interleukin 10
X-ray crystallographic studies, 490
Interleukin 12
X-ray crystallographic studies, 490
Interleukin 13
X-ray crystallographic studies, 490
Interleukin-1β- converting enzyme (ICE)
transition state analog inhibitors, 655
Interleukin 1 receptor
X-ray crystallographic studies, 490
Intermolecular forces, 6
InterPro, 349
InterProScan, 349
Intracellular adhesion molecule 1 (ICAM-1)
target of NMR screening studies using SAR-by-NMR, 566–567
Inventory data, 405
Inverse folding, 123–125
Inverse QSAR, 4
Inverted keys, 405
Ionic bonds, 6, 170,365
Ion-induced dipole interactions, 173
Ipconazole, 41
Irinotecan, 849,861
Irreversible inhibitors, 755
ISIS/Base, 377,387
ISIS databases, 373, 376–377, 387
descriptors, 192
exact match searching, 380
similarity searching, 382–383
substructure searching, 382
ISIS/Direct, 387
ISIS/Draw, 387
Isomer search, 388, 405–406
Isoprenaline, 885
Isotope editing and filtering, in NMR, 545,546

Iterative cyclic approaches
and combinatorial library design, 217
Ivermectin, 849,891,892

Japanese Patent and Trademark Documents database, 386
Jarvis-Patrick algorithm, 205,401
and combinatorial library design, 220,222
Java, 396,406,407
JG-365,121,122
Joins, 390,406
Journal content searching, 383

Kaempferol, 865
Kanomycin, 870,871
Karplus relationship, 525
Kelatorphan, 650,651
Kennard-Stone method, 65, 66
Ketoconazole, 717
8-Ketodeoxycoformycin, 751
Ketol-enol tautomerization
NMR spectroscopy, 527–528
Ketolides, 876
Ketones
pharmacophore points, 249
Key-based similarity searching, 382–383
Key field, 406
Keys, 363
encryption, 403
molecular similarity methods, 188
Khellin, 883, 884
Kinases
focused screening libraries targeting, 250
King's Clover, drugs derived from, 882
Kitz-Wilson plots, 757
K-means clustering, 401,406
K-medoids clustering, 406
K-Nearest Neighbors, 53, 62–63
KNI-272, 562
Knowledge-based scoring, 264–265,307,310–312
Knowledge-bases, 352,379
Knowledge Discovery in Databases (KDD), 394,406
Kohonen's Self-Organizing Map method, 65, 66
KOWWIN, 389
Kubinyi bilinear model, 3, 31

L-162,313, 669
L-364,286, 855
L-365,260,856
L-370,518, 660
L-685,434
structure-based design, 439
L-732,747
structure-based design, 440, 441
L-735,525, 797
L-746,072,211
L1210
growth inhibition, 37, 40–41
inhibition of DHFR, 32, 34
L. major DHFR, QSAR inhibition studies, 33
Laboratory information management systems, 377
β-Lactamase inhibitors, 718, 868–874
X-ray crystallographic studies, 483
β-Lactams, 868–874
Lamarckian genetic algorithm, 299
Lamivudine, 812–813,816
LASSOO algorithm, 217
Latent inactivators, 756
Latent semantic structure indexing, 255
Laudexium, 857,858
Lead generation, 426
Lead identification, 244
focused screening libraries for, 250–252
virtual screening for novel, 320–321
Lead molecule fragment analogs, 707–710
Leaf nodes, 377
Leave-one-out cross validation, 57, 64
Leave-some-out cross validation, 64
Legion, 387
Lennard-Jones potential, 285
Lentinan, 849
Leucine aminopeptidase inhibitors, 737–738
Leukocyte function-associated antigen 1 (LFA-1)
target of NMR screening studies using SAR-by-NMR, 566–567
Leukotreine A4 hydrolase
X-ray crystallographic studies, 491
Leveling effect, 722
Levorphanol, 708
LH-RH antagonist, 634
LH-RH peptidomimetic analog, 640
LibEngine, 221
LiBrain, 220
Libraries, 367, 400. *See* also Combinatorial libraries
focused screening libraries for lead identification, 250–252
for NMR screening, 574576
QSAR for rational design of, 68–69
Lidorestat
structure-based design, 448–449
Ligand-based design
NMR screening for, 564–577
NMR spectroscopy for, 510, 517–532
Ligand-based virtual screening, 188
Ligand design, 110–118
LigandFit
sampling/scoring methods used, 261
Ligand flexibility, *See* Flexible ligands
Ligands
macromolecule-ligand interactions, NMR spectroscopy, 510,517,535–562
non-peptidic ligands for peptide receptors, 667–674
visually assisted design, 110
Ligand strain energy, 308
LIGSITE, 291
Linear free energy relationship, 12, 14
Linear interaction energy method, 120
Linear notation, 368–369,406
Linear QSAR models, 26–28
descriptor pharmacophores, 61–62
Linear regression analysis
in QSAR, 8–11, 50, 53, 67
Line-shape, in NMR, 512
and ligand dynamics, 528–531
Lineweaver-Burk plot, 727, 729, 731
Link nodes, 381,397
LINUS (Local Independent Nucleating Units of Structure), 124
Linux, 396,406,411

Lipinski's "rule of 5"
and combinatorial library design, 214–215,216
in druglikeness screening, 245
for molecular similarityldiversity methods, 193,208
and NMR screening, 575
Lipocortin I
X-ray crystallographic studies, 491
Lipophilic interactions, 286
Liquid chromatography
for enantiomer separation, 787
Liquid chromatography-mass spectrometry (LC-MS), 586–591
affinity screening, 598–599
fast, 596
future developments, 607–608
gel permeation chromatography screening, 599
pulsed ultrafiltration screening, 603–606
for purification of combinatorial libraries, 592–594
structure/purity confirmation of combinatorial libraries, 594596
Liquid chromatography-NMR-MS, 608
Liquids
force field models for simple, 176
Liquid secondary ion mass spectrometry (LSIMS), 586,587
Lisinopril, 650, 881
asymmetric synthesis, 807, 809
Literature content searching, 383
LitLink, 387
Local stereochemistry, 398
Lock-and-key hypothesis, 251, 252
deformable models, 5
Locus maps, 140
Log 1/C, 25, 27–29
Log CR, 25
Logic, in query features, 406
Logic and Heuristics Applied to Synthetic Analysis (LHASA), 379
Log MW, 24
Log P
chloroform-octanol, 17
chromatographic determination, 17–18, 23
estimation systems, 388,389
for molecular similarity/diversity methods, 193,208
and polarity index, 26
Log Perm, 25
Log TA98, 25–26
Lomerizine, 41, 42
Lometrexol
structure-based design, 429–430
London forces, *See* van der Waals forces
Lopinavir, 648,659
asymmetric synthesis, 807, 809
Lorentz-Lorenz equation, 24
Lovastatin, 878–879
Low Mode Search, 292,301
LUDI, 259, 295–296, 315
combinatorial docking, 318
empirical scoring, 310
in molecular modeling, 112, 113
for novel lead identification, 321
LUMO (Lowest Unoccupied Molecular Orbital) energy, 11, 14, 26, 54
Luteinzing hormone β
X-ray crystallographic studies, 491
LuxS
X-ray crystallographic structure elucidation, 494–495
LW-50020,849
LY-303366,877
LY-315920
structure-based design, 454
Lycopene
positive ion APCI mass spectrum, 588
tandem mass spectrum, 591
Lymphomas, 718
Lysine
chemical modification reagents, 755

MACCS3D, 259,363
in molecular modeling, 111
MACCS (Molecular Access System), 254,361362
Machine learning techniques
in molecular modeling, 151
in QSAR, 62
Macrocyclic mimetics, 635–636
MACROMODEL, 94
Macromolecular structure determination, 334
NMR spectroscopy applications, 533535
Macromolecule-ligand interactions, *See* Protein-ligand interactions
Macrophage CSF 1
X-ray crystallographic studies, 491
MACROSEARCH, 94
Magnetization transfer NMR, 568–570
Ma *huang,* 884–885
Mandelate racemase inhibitors, 762,763
Manhattan distance, 68
Marcaine
classical resolution, 795
Marijuana, 853
Marine source drugs
antiasthma, 886
anticancer, 867–868
Markup languages, 371–372,405
Markush feature, 381
Markush structures, 367,368, 373,406
MARPAT, 385
Masoprocal, 849
Mass spectrometry, 583–592
affinity capillary electrophore* sis-mass spectrometry, 599–600
affinity chromatography-mass spectrometry, 598–599
bioaffinity screening using electrospray FTICR MS, 601–603
encoding and identification of combinatorial compounds and natural product extracts, 596–597
frontal affinity chromatography-mass spectrometry, 601
future directions, 607–608
gel permeation chromatography-mass spectrometry, 599
LC-MS purification of combinatorial libraries, 592–594
MS-based screening, 597–598
pulsed ultrafiltration-mass spectrometry, 603–606
solid phase mass spectrometric screening, 606–607

structure/purity confirmation of combinatorial compounds, 594–596
types of mass spectrometers, 585
Material Safety Data Sheets database, 386
Material Safety Data Sheet searching, 384
Matriptase
virtual screening of inhibitors, 269–271,272
Matrix-assisted laser desorption ionization (MALDI), 586, 596,606–607
Matrix metalloprotease inhibitors, 227,555457
chemical-shift mapping of binding to, 545
target of NMR screening studies using SAR-by-NMR, 566
target of structure-based drug design, 443–445
transition state analog inhibitors, 651–652
virtual screening, 315
Maximum Auto-Cross Correlation (MACC), 202
Maxmin approach, 208
May apple, drugs derived from, 865
Maybridge catalog, 385
MCDOCK
Monte Carlo simulated annealing, 297
MD Docking (MDD) algorithm, 298
MDL Information Systems, Inc. databases, 386–387
Mechanism-based enzyme inhibitors, 759–760,764–771
Mefloquine, 889–890
artemisinin potentiates, 887–888
Meglumine, 796–797
Melagatran
structure-based design, 442, 444
a-Melanotropin
conformationally restricted peptidomimetics, 637
Melatonin
analogs, 693
antagonists, 211–212
Melilotus officinalis (ribbed melilot), 882
Melittin
molecular modeling, 124
Members, of Rgroups, 368,406
Membrane-bound drug targets, 351
Membrane-bound proteins
molecular modeling, 154
NMR structural determination, 535
Membrane-bound receptors, 5
Mepartrican, 849
Meperidine, 708,851
rigid analog, 696
6-Mercaptopurine, 717
Mercury search program, 387
Merged Markush Service, 386
Merimepodip
structure-based design, 447
MERLIN, 39,386
Messenger RNA, ***See*** mRNA
Metabolism. ***See also*** Absorption, distribution, metabolism, and excretion (ADME)
enantiomers, 786–787
Metabolism databases, 385,386
Metabolism screening, 591
pulsed ultrafiltration application, 605
Metabolite database, 386
Metadata, 375,376,406
Meta-layer searching, 395
Metallopeptidase inhibitors
transition state analogs, 649–652
Metamitron, 42
Metazocine, 708
Metconazole, 41, 42
Methadone, 708
Methamphetamine
ring substitution analogs, 704
R-Methanandamide, 852,853
Methanol
force field models for, 176
Methicillin, 869, 870, 871
Methionine:adenosyl transferase, 148
Methionine hydrochloride
nonclassical resolution, 803
Methods in Organic Synthesis database, 385
Methotrexate, 717, 718, 749
interaction with dihydrofolate reductase, 120
structure-based design, 425
N-Methyl-acetemide
force field models for, 176
2-Methyl-1,4-benzenediol
allergenicity prediction, 833
a-Methyldopa, 785
5,10-Methylene-tetrahydrofolate, 426, 427
Methyl group roulette, 700
Methylphenidate (Ritalin)
classical resolution, 793–794
nonclassical resolution, 801
Metocurine, 856,857
Metoprolol
renal clearance, 38
Metropolis algorithm, 94, 98
D,L-Mevalonate, 745
Mevastatin, 744–745
MHC I receptor
homology modeling, 123
molecular modeling, 117
Michaelis-Menten constants, 725–728
use in QSAR, 7, 8
Michaelis-Menten kinetics, 725–728
Microarray chips, 334,344–345
Microbial secondary metabolites, 848
MicroPatent, 386
Microsoft Access, 373
Middle tier, 392, 406–407
Miglitol, 849
Milbemycins, 891,892
L-Mimosine
analogs, 690
MIMUMBA, 255
Mini-fingerprints, 255
Minimum topological difference (MTD) method, 4,147
Mining minima algorithm, 292, 299–300
Mitogen-activated protein kinase
target of structure-based drug design, 456–459
Mivacurium, 857,859
Mixtures, 367–368
Mizoribine, 849
MK-329,855
MK-383,213
MK-499,814–815,818
MK-0677,671,674
MK-678,657
ML-236B, 879
MLPHARE, 478
MM-25
structure-based design, 423, 424

MM-30
structure-based design, 423, 424
MM2 force field, 80, 307
MM3 force field, 80, 118
MM-PBSA method, 315
Modeling, *See* Molecular modeling
Model mining, 3
Model receptor sites, 149–150
Molar refraction, 24, 54
MOLCONN-Z, 55,192,389
Molecular Biology Database Collection, 345
Molecular comparisons, 138–142
Molecular connectivity, 192,407
estimation systems, 388
in QSAR, 26, 55, 56, 61
Molecular docking methods, *See* Docking methods
Molecular dynamic simulations. *See also* Monte Carlo simulations
barrier crossing, 98
with docking methods, 292, 298
and force field-based scoring, 308
hydrogen bonds, 107
in molecular modeling, 85, 93, 95–100,116–117,142
and non-Boltzmann sampling, 100
protein flexibility, 301–302
statistical mechanical, 94, 95
of temperature, pressure, and volume, 96
thermodynamic cycle integration, 99
in virtual screening, 263
water's role in docking, 302303
Molecular eigenvalues, 54
Molecular electrostatic potential, 102
Molecular extensions, 130–131
Molecular field descriptors, 54, 55–57
Molecular Graphics and Modeling Society, 360
Molecular holograms, 54
Molecular mechanics, 79–100
force fields, 174–177
Molecular modeling, 77–79, 153–154,358
affinity calculation, 118–122
and bioinformatics, 351
common patterns, 142–150
conformational analysis, 87, 93–94
and electrostatic interactions, 81–85
and force fields, 79–81
known receptors, 103–127
ligand design, 110–118
molecular comparisons, 138–142
and molecular mechanics, 79–100
pharmacophore *versus* binding site models, 127–135
potential surfaces, 85–89
protein structure prediction, 122–127
and QSAR, 5
and quantum mechanics, 100–103
similarity searching, 135–138
site characterization, 105–110
and statistical mechanics, 94–95
in structure-based design, 419, 420
systematic search, 89–94, 116
unknown receptors, 127–153
and virtual screening, 244
Molecular multiple moments, 54
Molecular property visualization, 137–138
Molecular recognition, 283
and hydrophobic interactions, 15
physical basis of, 284–289
Molecular replacement, 477
Molecular sequence alignment, 353
Molecular sequence analysis
bioinformatics for, 335–336
Molecular shape analysis, 53
Molecular shape descriptors, 54
Molecular similarityldiversity methods, 54, 188–190
analysis and selection methods, 203–209
combinatorial library design, 190,214–228
descriptors for, 191–203
example applications, 228–237
future directions, 237
and molecular modeling, 135–138
virtual screening by, 188,190, 209–214
Molecular structure descriptors in QSAR, 26
Molecular targets, *See* Drug targets
Molecular weight
for molecular similarity/diversity methods, 193,208
and QSAR, 24–25
MOLGEO, 255
Molinspiration, 390
MOLPAT, 110–111
Monasus ruber, 879
Monoamine oxidase inhibitors, 718
Monobactams, 873
Monocolin K, 879
Monomer Toolkit, 377378
Monte Carlo simulated annealing
and combinatorial library design, 218
with docking methods, 292, 297
with virtual screening, 263
Monte Carlo simulations. *See also* Molecular dynamic simulations
barrier crossing, 98
and combinatorial library design, 217
de novo design, 113
with docking methods, 292, 297–298
in molecular modeling, 85, 86, 93, 96–99, 116–117, 142
and non-Boltzmann sampling, 100
statistical mechanical, 94, 95
thermodynamic cycle integration, 99
in virtual screening, 263
Moore's Law, 393
Morgan algorithm, 378,407
Morphiceptin, 144,145
Morphinans, 850
Morphine, 634
ecological function, 848
fragment analogs, 707–708
Morphine alkaloids, 849–851
Mosflm/CCP4, 478
Most descriptive compound (MDC) method, 207–208
mRNA
and expression profiling, 340–341
MSDRL/CSIS, 361

MS-MS, *See* Tandem mass spectrometry (MS-MS)
Mulliken population analysis, **101–102**
MULTICASE SAR method
toxicity prediction application, **828–843**
Multidimensional databases, **390,407**
Multidimensional NMR spectroscopy, **512–514**
Multidimensional scaling, **201**
Multidimensional scoring, **291**
Multilevel chemical compatibility, **249**
Multiple-copy simultaneous search methods (MCSS), **298**
Multiple isomorphous replacement (MIR) phasing, **477**
Multiple regression analysis
in QSAR, 8–11, 50, 52, 53
Multisubstrate analog enzyme inhibitors, **720, 741–748**
Multi-tier architecture, **392, 407**
Multiwavelength anomalous diffraction (MAD) phasing, **474,477–478**
Munich Information Center for Protein Sequences (MIPS), **335**
Muscarinic receptors
distance range matrices, **136**
stereoisomer analogs, **705–706**
Mutation
in genetic algorithms, **87, 88**
MVIIA (Ziconotide)
NMR spectroscopy, **518–523, 526,534**
MVT-101, 103–104, 105, 117
Mycophenolate mofetil, **849**
Mycophenolic acid
structure-based design, **446–447**
Myoglobin, **419**

Nabilone, **853**
Nadolol
renal clearance, **38**
Naftifine, **717**
Na^+,K^+-ATPase inhibitors, **718**
Nalorphine, **850**
Naloxone, **850**
NAPRALERT, **597**
Naproxen
classical resolution, **794–795**
enzyme-mediated asymmetric synthesis, **805**
Narwedine, **802,803**
National Cancer Institute database, **222, 254, 385–386, 387**
National Center for Biotechnology Information (NCBI), **335**
sequence databases, **387**
National Toxicology Program, **246,829**
Natural product mimetics, **636**
Natural products
antiasthma drug leads, **883–886**
antibiotics drug leads, **868–878**
anticancer drug leads, **858–868**
antiparasitic drug leads, **886–891**
cardiovascular drug leads, **878–883**
CNS drug leads, **849–856**
drugs derived from, **1990–2000,849**
extract encoding and identification, **596–597**
leads for new drugs, **847–894**
neuromuscular blocking drug leads, **856–858**
NMR structure elucidation, **517–518**
Natural products databases, **387, 597**
Nearest neighbors methods, **53, 62–63, 67**
Neighborhood behavior, **211**
Nelfinavir, **648**
asymmetric synthesis, **817–818**
structure-based design, **440, 442**
Neomycin, **870,871**
Netropsin
binding perturbations, **544**
Neu5Ac2en
structure-based design, **451**
Neural networks, *See* Artificial neural networks
Neuraminidase inhibitors, **717**
flexible docking studies, **265**
PMF function application, **314**
ScreenScore application, **319**
target of structure-based drug design, **450–452**
X-ray crystallographic studies [int B virus], **491**
Neuroleptics
molecular modeling, **150**
Neuromuscular drugs
natural products as leads, **856–858**
Neuropeptide Y
X-ray crystallographic studies, **492**
Neuropeptide Y inhibitors, **671, 673,674**
Neutral endopeptidase (NEP), **650–651**
Nitric oxide synthase, **736**
Nitric oxide synthase inhibitor, **738–739**
Nivalin, **892**
NK receptor antagonists, **669–670,672**
NMR, *See* Nuclear Magnetic Resonance (NMR) spectroscopy
NMR timescale, **537**
NN-703,671,675
NOE, *See* Nuclear Overhauser effects (NOE), in NMR
Nolatrexed, **428**
Non-Boltzmann sampling, **100**
Nonclassical bioisosteres, **690–694**
Nonclassical resolution, of chiral molecules, **799–804**
Noncompetitive inhibitors, **730–731**
Noncovalent bonds, **6,170**
energy components for intermolecular drug-target binding, **171–174**
Noncovalently binding enzyme inhibitors, **720–754**
Nonisosteric bioanalogs, **689–694**
Nonlinear QSAR models, **28–29**
descriptor pharmacophores, 62–63
Nonlinear regression, **67**
Non-overlapping mapping, **398**
Non-peptide peptidomimetics, **636,657–674**
Nonpolar interactions, *See* van der Waals forces
Nonstructural chemical data, **373**
Norapomorphine
alkyl chain homologation analogs, **701**

Norfloxacin, 41, 42
Norstatine, 652
Norvir
structure-based design, 438, 440
Nostructure, 410
NOT logical operator, 406
NPS 1407,812,815
Nuclear hormone receptors
focused screening libraries targeting, 250
Nuclear Magnetic Resonance **(NMR)** imaging, 510
Nuclear Magnetic Resonance **(NMR)** screening methods, 510,562-577
capacity issues, 190
Nuclear Magnetic Resonance **(NMR)** spectroscopy, 351, 507–514,592. ***See*** also **SAR**-by-NMR approach
applications, **516–517**
chemical shift mapping, 543–545
instrumentation, 514–516
with LC-MS, 608
ligand-based design, 510, **517–532**
macromolecule-ligand interactions, 510, 517, **535–562**
metabolic, 510
and molecular modeling, 78
multidimensional, 512–514
for pharmacophore modeling, 531–532
receptor-based design, 510, 532–562
in structure-based drug design, 419,516–517
and structure-based library design, 225
structure determination of bioactive peptides, 517–518
structure elucidation of natural products, **517–518**
and virtual screening, 244
Nuclear Magnetic Resonance (NMR) titrations, 545
Nuclear Overhauser effect **(NOE)** pumping, 573
Nuclear Overhauser effects **(NOE),** in NMR, 511,512
for conformational analysis, 525
and distance range matrix, 136
for macromolecular structure determination, 533
and NMR screening, **571–573**
NOE docking, 545–546
transferred NOE technique, 532
Nucleic acid receptors, 5
Nucleic acids. ***See*** also DNA, RNA
biochemical force fields, 175–176
NMR structural determination, 535
Nucleotide intercalation, 183

O (graphics program), 478
Object-oriented language, 407
Object relational database, 407
Ocreotide, 657
Octanol/water partitioning system, 16–17
OLAP (**OnLine** Analytical Processing), 390,408
Oleandomycin, 870,871
OLTP (**OnLine** Transaction Processing), 390,408
Omapatrilat, 651
OMEGA, 255
Ondanetron
nonclassical resolution, 802
OpenBabel, 372
Open Molecule Foundation, 360
Open reading frames
housing in DNA databases, 338
Opium poppy, 848,849
Optimization approaches
for combinatorial library design, 217–220
OptiSim method, 207
and combinatorial library design, 220
Oracle, 373
Organic structure databases, 385
Organoarsenical agents, 717
Orientation map **(OMAP),** 131, 144,146
Oriented-substituent **pharma**cophores, 224
Orlistat, 848,849
OR logical operator, 406
use in molecular **similarity/** diversity methods, 194
Ornithine decarboxylase inhibitors, 717, 766, 768, 769
Oseltamivir, 452, 717
OSPPREYS (**Oriented-Substitu**ent Pharmacophore **PRop-ErtY** Space), 199,224
Overlapping mapping, 398
OWFEG (one window free energy grid) method, 308,315
Oxidation
enzyme-mediated asymmetric, 806
Oxidoreductases
target of structure-based drug design, 445–449
Oxprenolol
renal clearance, 38
Oxytetracyclin, 870

P. carinii DHFR, QSAR inhibition studies, 32–33
Pacific yew, **paclitaxel** from, 861–862
Paclitaxel, 843,848,861–863
Pairwise interactions, 79–80
PALLAS System, 389
Paluther, 887
Pamaquine, 888–889
Pancreatic polypeptide
molecular modeling of avian, 124
Papain
QSAR studies, 5
transition state analog inhibitors, 654
Papaver somniferum (opium PoPPY), 848,849
Parallel chemistry, 283
Parallel library, 214
Parallel processing, 408
Parathion, 774
Parathyroid hormone
X-ray crystallographic studies, 492
Parent structure, 368,404
Pareto **optimality,** 220
Partial charge, 366,373
Partition coefficients, 16–17, 54
Partition function, 94–95
Partitioning algorithms, 67
PASS, 291,390
Patent Citations Index, 386
Patent databases, 386
Patent searching, **383–384**
Pathways, 495–496
X-ray crystallographic analysis, 495–496
Pattern recognition, 408
and cluster analysis, 401
with QSAR, 53

PC cluster computing, 283–284
PCModels, 386
PD-119229
structure-based design, 460–461
PDB file format, 369
PDGF beta
X-ray crystallographic studies, 492
Peak intensities, in NMR, 512
Peldesine
structure-based design, 460
Pemetrexed
structure-based design, 429–430
Penicillins, 717,868–870
preventing bacterial degradation, 718
Penicillipepsin inhibitors
molecular modeling, 116
Penicillium *brevicompactum,* 879
Penicillium chrysogenum, 869
Penicillium *citrinium,* 879
Pentostatin, 717, 750–751,849
PeptiCLEC-TR, 804
Peptide backbone mimetics, 636, **644–645**
Peptide bond isosteres, 644–646
Peptides, 634
biochemical force fields, 175–176
NMR structural determination of bioactive, 517–518
non-Boltzmann sampling of helical transitions, 100
Peptidomimetics, 128–129, 633–634
classification, 634–636
conformationally restricted peptides, 636–**643**
future directions, 674–677
molecular modeling, 154
non-peptide, 636,657–674
peptide bond isosteres, 644–646
protease inhibitors, 646–655
speeding up research, 655–657
template mimetics, **643–644**
Peramivir
structure-based design, 452
Personal chemical databases, 387–388
Petabyte, 408
Pethidine, 851
PETRA, 390
Petrosia *contignata,* 886
Pfam, 349
Pharmacophore keys, 376, 408–409
Pharmacophore mapping, 255
Pharmacophore point filters, 196,249–250
Pharmacophores, 368
with BCUT descriptors, 223–224
binding site models contrasted, 127–135
defined, 252–253,408
descriptor, for ***QSAR,*** 60–63
3D searching, 366–367
in molecular modeling, 110
for molecular **similarity/diversity** methods, 194–201, 204–206
NMR-based modeling, 531–532
NMR spectroscopy-based modeling, 531532
oriented-substituent, 224
site-based, 235–237
virtual screening, 252–260
PharmPrint method, 223
Phase problem
in X-ray crystallography, 476–478
Phencyclidine
rigid analogs, 696–697
***β*-Phenethylamines,** 697–698
Phenols
DNA synthesis inhibition by, 40
growth inhibition by, 38, 40–41
Phenylacetic acids
ionization of substituted, 12–14
Phenylethanolamine***N*-methyl-transferase (PNMT)** inhibitors, 733–734,740
(R,S)-α-Phenylglycidate, 762
***(S)*-α-Phenylglycidate,** 762
***N*′-(*R*-Phenyl)sulfanilamides**
antibacterial activity, 10
Phosphatidylcholine monolayers
penetration by ROH, 27
Phosphocholine
docking to antibody McPC603, 298
Phosphodiesterases
alignment of catalytic domains in gene family, **349**
Phospholipase A2
homology modeling, 123
target of structure-based drug design, 453–454
X-ray crystallographic studies, 492
Phosphonoacetate, 740
N-Phosphonoacetyl-L-aspartate **(PALA)**, 743–744
Phosphonoformate, 740
2-(Phosphonomethoxy)ethylguanidines
chain branching analogs, 702
***(R)*-9-[2-(Phosphonomethoxy)propyl]adenine (*R*-PMPA)**, 818–819
Phosphoryl transferases
target of structure-based drug design, 456–4561
Phylogenomics, **347–349**
Physicochemical descriptors, 54
estimation systems, 389
for molecular **similarity/diversity** methods, 193
for virtual screening, 255
Physicochemical properties, 373, 409
Physostigmine, 774
Picornaviruses
target of structure-based drug design, 454–456
Picovir
structure-based design, 455–456
Pigeon liver DHFR, ***QSAR*** inhibition studies, 31-32
Pipecolic acid, 805
Pirlindole
chromatographic separation, 788–789,790
Pit viper, drugs derived from, 881
Pivoting data, 409
Plant natural products, 848,893
Plant secondary metabolites, 848
Pleconaril
structure-based design, 455–456
PLOGP, 389
PLP function, 266,309
consensus scoring, 320
hydrophobic interactions, 319
performance in structure prediction, 314
seeding experiments, 319
PLUMS, 225

p38 MAP kinase
consensus scoring study, 266
seeding experiments, 318319
PMF function, 265, 311, 312
performance in structure prediction, 314
seeding experiments, 319
PMML (Predictive Model Markup Language), 405
PNU-107859
NMR binding studies, 555
PNU-140690, 659, 812, 813
PNU-142372
NMR binding studies, 555–556
POCKET, 259
Podophyllin
drugs derived from, 865–867
Podophyllotoxin, 849, 865–866
Podophyllum emodi, 865
Podophyllum peltatum (May apple), 865
Poisson-Boltzmann equation, 83, 84
Polarity index, 26
Polarizability, 85
Polarizability index, 11
Polarization energy, 173
Polar surface area
in druglikeness screening, 245
Policosanol, 849
Pomona College Medchem, 385
Potassium channel shaker
X-ray crystallographic studies, 492
Potential smoothing, 86
Potential surfaces, 85–89
PPAR γ
X-ray crystallographic studies, 492
Pralnacasan
structure-based design, 443, 446
Pravastatin, 879, 880
Preliminary screening, 111-112
Pressure
molecular dynamic simulation, 96
Primaquine, 889
Principal components analysis
with molecular similarity/diversity methods, 192, 201
in QSAR, 15
Principal components regression, 53
Prindolol
renal clearance, 38
Prinomastat
structure-based design, 444, 446
PRINTS, 335, 349
Privileged structures
in molecular similarity/diversity methods, 209
template mimetics, 644
in virtual screening, 251-252
PROBE, 126
PROCHECK program, 478
ProDock
affinity grids, 293
Monte Carlo minimization, 298
ProDom, 349
Proflavin
thermodynamics of binding to DNA, 183
Progesterone receptor
antibody FAB fragment, 128
X-ray crystallographic studies, 492
PROGOL, 67
Project Library, 387
Prolactin receptor
X-ray crystallographic studies, 492
PRO–LEADS, 299
assessment, 303, 304
flexible ligands, 263
PRO–LIGAND
genetic algorithm with, 89
Pronethalol, 881
Propargylglycine, 719-720
Property-based design, 234-235
Propranolol, 881–882
enantiomers, 786
enzyme-mediated asymmetric synthesis, 805–806
renal clearance, 38
*N*10-Propynyl-5,8-dideazafolate, 426, 427
Proresid, 866-867
PRO-SELECT
combinatorial docking, 318
PROSITE, 348349
Prostacyclin, 762-763
Prostaglandin synthase inhibitors, 718, 762-763, 764
Protaxols, 863
Protease inhibitors. See also HIV protease inhibitors
affinity labels, 762
QSAR studies, 5
structural genomics, 353
target of structure-based drug design, 432-445
transition state analogs, 646-655
Protein classes, 262
Protein Data Bank, 110, 353
sequence database, 387
X-ray crystallography application, 478-479
Protein Database
and virtual screening, 261-262
Protein families
targeting in libraries for virtual screening, 251
Protein interactions, 334
Protein-ligand docking programs, 292
Protein-ligand docking techniques, 262-264
Protein-ligand interactions, 284-289, 322
NMR spectroscopy, 510, 517, 535–562
QSAR studies, 5
scoring, 264-267
scoring in virtual screening, 264-266
Protein-protein interactions, 634
characterizing, 637
Proteins. See also Macromolecular structure determination
binding and chirality, 786-787
flexibility and docking, 300-302, 322
phylogenetic profiling, 347–348
Protein structures
prediction, 122-127
in structure-based virtual screening, 261-262
X-ray crystallographic analysis, 496
Proteome, 352
Proteomics. 409
Pseudoirreversible enzyme inhibitors, 771-774
Pseudomonas acidophila, 873
Pseudopeptides, 635-636
isosteres replacing peptide backbone groups, 646
Pseudoracemate, 799-800, 801
Pseudo-receptor models, 261
PSI-BLAST, 335, 347
X-ray crystallography application, 481
Pulsed ultrafiltration-mass spectrometry, 603-606

Purine biosynthesis inhibitors, 752
Purine nucleoside phosphorylase
target of structure-based drug design, 459–461
Purine ribonucleoside, 751–752
Purity verification
as bottleneck in drug discovery, 592
LC-MS-based purification, 592–594
mass spectrometry application, 594–596
Pyridoxal phosphate-dependent enzymes
mechanism-based inhibitors, 765–768
Pyrimidine biosynthesis inhibitors, 752
Pyrrolinones
peptide-like side chains, 635, 642
Pyruvate dehydrogenase inhibitors, 717
Pyruvate kinase, 764

Qinghaosu (artemisinin), 886
Q-jumping MD, 298
QSAR, *See* Quantitative structure-activity relationships
QSAR and Modeling Society, 360
QSDock, 295
QSiAR, 53, 60
QSPR, *See* Quantitative structure-property relationships
Quadratic shape descriptors, 295
Quadrupole time-of-flight hybrid (QqTOF) mass spectrometry, 585,607
QUANTA, 258
Quantitative structure-activity relationships, 1–4, 49–52, 358. *See also* Comparative quantitative structure-activity relationships; 3D quantitative structure-activity relationships
applications with interactions at cellular level, 37–38
applications with interactions *in vivo,* 3839
applications with isolated receptor interactions, 30–37
2D, 52, 53
data mining, 66–67
defined, 409
descriptor pharmacophore concept, 60–63
and docking methods, 304–305
Free-Wilson approach, 4, 29–30
guiding principals for safe, 66
and library design, 68–69
linear models, 26–28, 51, 61–62
model validation, 63–66
and molecular similarity/diversity methods, 194
multiple descriptors of molecular structure, 54–58
nonlinear models, 28–29, 51, 62–63
parameters used, 11–26
problems with Q^2, 64–65
receptor theory development, 4–7
standard table, 51
in structure-based design, 419
substituent constants for, 19–23
taxonomy of approaches, 52–54
tools and techniques of, 7–11
training and test set selection, 65–66
variable selection. 60–63
as virtual screening tool, 66–69
Quantitative structure-property relationships, 53
and molecular similarity/diversity methods, 194
Quantum chemical indices, 11, 14–15, 54
Quantum mechanics, 100–103
Quercetin, 865
Query features, 381
logical operators, 406
Query structures, 368
mapping, 380
Quinacrine, 889,890–891
Quinine, 888–891
Quinolines, 889–890
Quinupristin, 876–877
Quisqualic acid, 694
QXP
Monte Carlo minimization, 298

Rabbits
narcosis induction by ROH, 27
Racemates, 782
types of, 799–801
Racemization, 783–784
Radiation damage
in electron cryomicroscopy, 612–613,614–615,616
Raffinate, 791
Ramachandran plot, 92
and conformational mimicry, 141
Ramipril, 746
Ramiprilat, 746–747
Random searching
in virtual screening, 263
Rapamycin, 848
binding to FKBP, 552,554
Rapid, reversible enzyme inhibitors, 720,728–734
Rapid sequence screening, 334
Rare gas interactions, 174
Ras-farnesyltransferase inhibitors
non-peptide peptidomimetics, 665–667,668,669
template mimetics, 643,645
Rats
ataxia induction by ROH, 29
liver DHFR, QSAR inhibition studies, 34
REACCS, 398
reaction searching using, 383
Reactant-biased, product-based (RBPB) algorithm, 215,216, 219
Reacting centers, 366,383, 398, 409
Reaction Browser/Web, 387
Reaction databases, 386
Reaction field theory, 83
Reaction indexing, 383
Reaction Package, 386
Reactions, *See* Chemical reactions
Reaction scheme, 409
Reagent Selector, 387,391–392
RECAP (Retrosynthetic Combinatorial Analysis Procedure), 249
Receptor-based design
NMR spectroscopy for, 510, 532–562
pharmacophore generation, 259
Receptor-based 3D QSAR, 304
Receptor-ligand complexes, 78
Receptor-ligand mimetics, 636
Receptor mapping, 148–149

Receptor-relevant subspace, 204, 222
Receptor theory, 4–7
Reciprocal nearest neighbor, 220
Recursive partitioning, 247–248
Red clover extract
  LC-MS mass spectrum, 589, 590
Reduction
  enzyme-mediated asymmetric, 806
Refining, search queries, 409
REFMAC, 478
Registration, of chemical information, 377–379
Registry number, 378–379,409
Relational databases, 363, 373, 409
Relative diversity/similarity, 209
Relaxation parameters, in NMR, 511,512
  changes on binding, 536–537
  and ligand dynamics, 528–531
  and NMR screening, 571–573
  in receptor-based design, 534
Relenza
  structure-based design, 451
Relibase, 315
Reminyl, 892
Renin inhibitors, 432
  molecular modeling, 123, 153
  transition state analogs, 647
REOS filtering tool, 225
RESEARCH
  Monte Carlo simulated annealing, 297
Resiniferatoxin, 854
Restrained electrostatic potential, 102
Result set, 409,411
Retigotine, 783
Retinoic acid
  docking and homology modeling, 305
  stereoisomer analogs, 707
  X-ray crystallographic studies, 492–493
Retinoid X receptor
  X-ray crystallographic studies, 493
Retrosynthetic analysis, 409
Retrothiorphan, 650, 651
Reverse nuclear Overhauser effects pumping, 573
Reversible enzyme inhibitors, 720
RGD peptide sequence mimics, 129,643,645,662–665
Rgroups, 368,373,397,405, 409–410
  and combinatorial library design, 221
Rhinoviruses
  comparative molecular field analysis, 153
  molecular modeling of antiviral binding to HRV-14, 120, 122
  target of structure-based drug design, 454–456
Rhodopeptin
  template mimetics, 644,645
Ribbed melilot, drugs derived from, 882
Rifamycin, 870,872
Rigid analogs, 694–699
Rigid body rotations, in molecular modeling, 90–91
Rigid docking, 262–263,293
Rigid geometry approximation, in molecular modeling, 89
Ring-position isomer analogs, 699–704
Rings
  in druglikeness screening, 245
  molecular comparisons, 139
  in molecular modeling, 91
Ring-size change analogs, 699–704
Ritalin
  classical resolution, 793–794
  nonclassical resolution, 801
Ritonavir, 648,659
  asymmetric synthesis, 807–808,809
  structure-based design, 438, 440
Rivastigmine, 774
  structure-based design, 449–450
RNA
  molecular modeling, 154
  NMR structural determination, 535
RNA polymerase inhibitors, 717
Ro-31-8959,121
Ro-32-7315, 652, 653
Ro-46-2005,673, 676
ROCS, 256,259
  shape-based superposition, 260
Roll-up, 410
Root structure, 368,404,410
ROSDAL notation, 368,410
Rosuvastatin, 848, 880–881
Rosy periwinkle, vinca alkaloids from, 858
Rotatable bonds
  in druglikeness screening, 245
  in molecular modeling, 90–91
Royal Society of Chemistry Chemical Information Group, 360
RPR109353, 211
R,S descriptors, for chiral molecules, 365, 783
RS^3 Discovery System, 377,385
RSR-13,422,423
RSR-56,422,423
RTECS, 246
RUBICON, 386
  virtual screening application, 254
"Rule of 5," See Lipinski's "rule of 5"

S-37435,675
Saccharomyces cerevisiae
  genome sequencing, 344
Saccharopolyspora erythraea, 874
Salbutamol, 885,886
Salmeterol, 885,886
S-Salmeterol
  enzyme-mediated reduction, 806,808
Salmonella
  mutagenicity prediction, 829, 831–832,840,842–843
Salt bridges, 285
  and virtual screening, 272
Salts definitions, 376
Salts search, 388
Sampatrilat, 651
Saquinavir, 648,659, 717
  structure-based design, 435–437,440
SAR-by-NMR approach, 508, 516
  in NMR screening, 564468, 576
Sarin, 774
Saturated rings
  analogs based on substitution of aromatic for saturated ring; or the converse, 699–704
Saturation diversity approach, 223

Saturation transfer difference NMR, 568–570
SB203580
structure-based design, 457
SB209670, 211, 675
SB214857, 213
SB242253
structure-based design, 458
Scaled particle theory, 84
SCH 47307,667
SCH 57939,808,810
SCH 66701,667
Schrodinger equation, 79,363
Scientific and Technical Information Network, 597
SciFinder, 385
SCOP, 353
X-ray crystallography application, 494
ScoreDock
assessment, 303
Scoring functions, 261,264–266, 306–312,322
assessment, 312–315
basic concepts, 289–290
and molecular modeling, 115–116
overview of, 307
penalty terms, 313
Screening. *See* also Combinatorial chemistry; High-throughput screening; Virtual screening
mass spectrometry-based, 597–598
solid phase mass spectrometric, 606–607
ScreenScore, 319
Sculpt, 387
SEAL, 316,321
Search queries, 368
β-Secretase inhibitors
transition state analogs, 649
Selector, 387
SELECT program, 218–219,221
SELECT statement, 404,406
Self-Organizing Map method, 65, 66
Semirigid analogs, 694–699
Sequence assembly, 342
Sequence comparison, 334
bioinformatics for, 346-347, 352–353
Sequence databases, 387
Sequences, 363–364
Sequential docking, 317
Sequential simplex strategy, 11
Serevent, 806
Serial analysis of gene expression (SAGE),344
Serine
chemical modification reagents, 755
Serine peptidase inhibitors
transition state analogs, 652–655
Serine protease inhibitors
affinity labels, 762
common structural motifs, 494
QSAR studies, 5
Serotonin
conformationally restricted analog, 696
ring position analogs, 703–704
Serotransferrin β
X-ray crystallographic studies, 493
Serum albumin
binding of enantiomers, 786
mass-spectrometric binding assay screening, 604
target of NMR screening studies, 567–568,573
SFCHECK program, 478
Sgroups, 373,397,405,410
Shake and Bake, 477,478
SHAPES
NMR screening libraries, 575
and SAR-by-NMR, 568
SHARP, 478
SHELX, 478
Sialic acid, 450–451
Sialidase
genetic algorithm study of docking, 88–89
Sickle-cell anemia, 419–425
Side chains
of known drugs, and druglikeness screening, 248–249
peptide-like, 635, 642
Signature
molecular similarity methods, 188
Similarity searching, 379, 382–383, 410. *See* also Molecular similarity/diversity methods
in molecular modeling, 135–138
and QSAR, 67–68
SQL for, 395
Simulated annealing. *See* also Monte Carlo simulated annealing
and combinatorial library design, 217
with FOCUS-2D method, 68
hydrogen bonds, 107
in molecular similarity/diversity methods, 205
with QSAR, 53, 61
in virtual screening, 263
Simulated moving bed chromatography
for enantiomer separation, 787,789–793,821
Simvastatin, 719, 744,879,880
Single nucleotide polymorphism (SNP) maps, 338–340
Single-wavelength anomalous diffraction phasing (SAD), 477–478
Sirolimus, 848,849
Site-based pharmacophores, 235–237
Size-exclusion chromatography, 599
Sizofilan, 849
SKF 107260,663
SLIDE
anchor and grow algorithm, 296
combinatorial docking, 317
explicit water molecules, 302
geometric/combinatorial search, 295
ligand handling, 293
protein flexibility, 301
receptor representation in, 291
SLN (Sybyl Line Notation), 369, 410
Slow-binding enzyme inhibitors, 720,734–740,749
Slow-tight-binding enzyme inhibitors, 720, 734–740
SMART, 349
functional group filters, 246
SMILES notation, 254,410
and canonical renumbering, 378
described, 368–369,371
use with comparative QSAR, 39
SmoG, 311
SN-6999,544
Snowdrops, drugs derived from, 892

SNX-111,851–852
SOCRATES, 361
Sodium cromoglycate, 883–884
Soergel distance, 68
Solid Phase Synthesis database, 385
Solution molecular dynamics, 528
Solvation effects
  and docking scoring functions, 307,308,310
  drug-receptor complexes, 177–179
  molecular modeling, 83–85
SOLVE, 478
Somatostatin
  conformationally restricted peptidomimetics, 129,637, 638
  receptor agonists found through combinatorial chemistry, 657
  template mimetics, 643–644, 645
Sorangium cellulosum, epothilones from, 864
SPC model, 175
Specific structure, 368,403
Sphere coloring, 296
Sphere-exclusion, 207
Spindle poisons, 867
Spin-label NMR screening, 573–574
SPLICE, 89,113
Spongothymidine, 867–868
Spongouridine, 867–868
SPRESI, 254
SPRESI'95, 385
SQL (Structured Query Language), 395,410
SR-48968,670
SR-120107A, 670,673
SRS (Sequence Retrieval System), 335
Standardization
  bioinformatics, 337
Star schema, 390,391,410
Statins, 719,848
  multisubstrate analogs, 744–746
Statistical mechanics, 94–95
Stem cell factor
  X-ray crystallographic studies, 493
Stereoisomer analogs, 704–707
Stereoisomers, 365–366, 783–785
Stereoplex, 387
Stereoselective synthesis, *See* Asymmetric synthesis
Steric parameters
  in QSAR, 23–25, 52
STERIMOL parameters, 24, 50
Steroid 5α-reductase inhibitors, 717,768–770
  QSAR studies, 37–38
Steroids
  affinity for binding proteins, 147
  biosynthesis inhibition, 770
STN Express, 385
STN International, 385
STO-3G basis set, 175
Storage, of chemical information, 373–377
Streptavidin
  free energies of binding, 286
  genetic algorithm study of biotin docking to, 89
  interaction with biotin, 181–183
Streptogramins, 876–877
Streptomyces, 876,891
Streptomyces cattleya, 872
Streptomyces clavuligerus, 869
Streptomyces erythreus, 874
Streptomyces griseus, 869
Streptomyces venezuelae, 870
Streptomycin, 869–870
Stromelysin
  flexible docking studies, 265
  NMR binding studies, 555–557
  target of NMR screening studies using SAR-by-NMR, 566
  target of structure-based drug design, 443–444
Structural data mining, 410
Structural frameworks of known drugs
  and druglikeness screening, 248–249
Structural genomics, 283
  and bioinformatics, 352354
  and X-ray crystallography, 481,494–496
Structural homology, *See* Homology
Structural similarity, 255
Structure-activity relationships. *See also* Quantitative structure-activity relationships
  and data mining, 66–67
  and molecular modeling, 134
  nonlinear, 62
  pharmacophore searching for generating, 255,272–273
  and toxicity prediction, 828–843
Structure-based drug design, 358,417–419,467–469
  antifolate targets, 425–432
  and combinatorial chemistry, 227
  combinatorial library design, 225–228
  and docking studies, 282, 321–322
  hemoglobin, 419–425
  hydrolases, 449–454
  iterative cycles, 282,463
  NMR spectroscopy for, 419, 516–517
  oxidoreductases, 445–449
  phosphoryl transferases, 456–461
  picornaviruses, 454–456
  proteases, 432–445
  and virtual screening, 244
Structure-based inhibitor design, 418
Structure-based virtual screening, 260–267
Structure elucidation
  NMR spectroscopy for, 517–525
Structure table, 376
Structure verification
  as bottleneck in drug discovery, 592
  mass spectrometry application, 594-596
Subgraph isomorphism, 67,405, 410
Subreum, 849
Substance P antagonists, 669–671
Substances, 368,410
Substituent constants, for QSAR, 19–23
Substrate analog enzyme inhibitors, 733
Substructure searching, 255, 379,381–382,410–411
  and QSAR, 67
  SQL for, 395
Substructure search keys, 375, 376,378,410
  molecular similarity/diversity methods, 189,221

Subtilases
homology modeling, 123
Succinate dehydrogenase, 733
Succinic semialdehyde dehydrogenase inhibitors, 718
Succinyldicholine
conformationally restricted analogs, 699
Sugars
chirality, 784
Suicide substrate MMP inhibitors, 651–652
Suicide substrates, 756
Sulbactam, 718
Sulfonamides
pharmacophore points, 249
Sulfones
pharmacophore points, 249
Sulfonyl halides
filtering from virtual screens, 246
Sulphonamides, 717
Supercritical fluid chromatography
for enantiomer separation, 787
Supercritical fluid chromatography-mass spectrometry (SFC-MS)
for combinatorial library purification, 594
Superstar, 315
Superstructure search, 255,257, 411
Supervised data mining, 66–67, 411
Suxamethonium, 857
Sweet clover, drugs derived from, 882
Sweet wormwood, drugs derived from, 886
SWISS-PROT, 335,345–346
SYBYL, 130
Sybyl Programming Language, 378,410
Synercid, 848,849, 876
SYNLIB, 361
SYSDOC
ligand handling, 293
Systematic search
and Active Analog Approach, 144–145
and conformational analysis, 89–93
in docking methods, 292
in molecular modeling, 89–94, 116
T. gondii DHFR, QSAR inhibition studies, 33
Tabular storage, 369–371
Tabu search
with docking methods, 292, 299
in virtual screening, 263
Tachykinin receptors, 669
Tacrine, 58
structure-based design, 449
Tacrolimus, 848,849
Tadpoles
narcotic action of ROH, 28–29
Tagging approaches, 596–597
TAK-029,213
TAK-147
structure-based design, 450
Tandem mass spectrometry (MS-MS),590–591
of combinatorial libraries, 592
for structure determination of bioactive peptides, 518
types of mass spectrometers, 585
Tanimoto coefficient, 68,202, 411
cluster-based methods with, 206
and similarity searching, 382, 410
for virtual screening, 210
Tanimoto Dissimilarity, 220
Tanomastat
structure-based design, 444–445,446
TargetBASE, 348
Target class approach, 188, 228–234
Target discovery. See also Drug targets
bioinformatics for, 335, 338–345
TAR RNA inhibitors, 103
Tautomenzation
NMR spectroscopy, 526–528
Tautomers, 366
Tautomer search, 388,405–406
Taxol, 843,848,861–863
HMBC spectroscopy, 518
NMR spectroscopy, 525–526, 531
Taxol side-chain, 803–804
Taxus baccata (English yew), 861–862
Taxus brevifolia (Pacific yew), 861–862
TB36
structure-based design, 424–425
TBC 3214,674,676
Team Works, 377
Teicoplanin, 849
Telithromycin, 848,876
Temperature
molecular dynamic simulation, 96
Template mimetics (peptidomimetics), 643–644
Tendamistat
NMR relaxation measurements, 528–529,535
Teniposide, 867
Teprotide, 746,881
Terabyte, 411
Terbinafine, 717
Testosterone, 36, 768, 771
A,-Tetrahydrocannabinol (THC), 852–853
Tetrahydrofolate, 425
Tetrahymena pyriformis
growth inhibition, 27, 37–38
spiro-Tetraoxacycloalkanes
ring-size analogs, 702–703
Tetrazoles, 135
as surrogates for cis-amide bond, 141–142
Thalidomide, 783–784,785
Thebaine, 850,851
Theilheimer/Chiras/Metalysi database, 386
Therapeutic area screening
molecular similarity/diversity methods, 191
Thermodynamic cycle integration, 99–100,120–121
Thermolysin inhibitors
genetic algorithm study of active site, 89
molecular modeling, 117, 120, 121,151–153
novel lead identification, 321
transition-state analogs, 749–750
Thick clients, 400–401,411
Thienamycin, 872,874
Thin clients, 363,392,401,411
Thiobiotin
binding to avidin, 181, 182
Thioesters
filtering from virtual screens, 246
β-ThioGARdideazafolate (β-TGDDF), 742–743

Thiol proteases
QSAR studies, 5
Thiomuscimol, 690
4-Thioquinone fluoromethide, 770
Thioridazine, 805,806
Thiorphan, 650,651
Thor database manager, 386
Thor system, 377
exact match searching, 380381
Threading, 123–125
3D descriptors
molecular **similarity/diversity** methods, **55–58, 191–201**
validation, 211–213
Three-dimensional electron cryomicroscopy, **615–616**
3D models, 363,366–367, 397–398
3D pharmacophores
filter cascade, 267
for molecular **similarity/diversity** methods, 194–201
for searching, 381–382
similarity searching, 189,383
for virtual screening, 210, 255–259
3D quantitative **structure-activity** relationships (**3D-QSAR**), **52, 53, 58–60**
and molecular modeling, 115, 138
3D query features, 368,381382, 398
3DSEARCH, 111,259
3D structure databases, 387
3-Point pharmacophores, 376, 408
molecular similarity methods, **189, 195–196, 198**
for virtual screening, 210
Threo- prefix, 784
Threose
enantiomers, 784
Thrombin inhibitors, 227
combinatorial **docking**, 318
force field-based scoring study, 307
molecular modeling, 116
non-peptide peptidomimetics, 660–662,663,664
seeding experiments, 319
site-based pharmacophores, 235–236
target of structure-based drug design, 442–443
Thromboxane 4, 762–763
Thymidine **kinase** inhibitors, 717
role of water in **docking**, 303
X-ray crystallographic studies, 493
Thymidylate **synthase** inhibitors, 227, 717
target of structure-based drug design, 425,426–429
Thymitaq, 428
Thyroid hormones
NMR spectroscopy, **529–531**
Thyroid receptor beta, 263
Thyroliberin
peptidomimetics, 129
Thyrotropin-releasing hormone, 637
Thyroxine
NMR spectroscopy, 529–531
Tight-binding enzyme inhibitors, 720, 734–740, 749
Time-of-flight mass spectrometry, 585,607
Timolol
renal clearance, 38
TIP3P model, 175
Tipranavir, 812, 813
Tirilazad mesylate, 849
Titrations
NMR application, 545
TNF-a converting enzyme (**TACE**), 652
Tolamolol
renal clearance, 38
Tolrestat
structure-based design, 448
Tomudex, 427
Toolkits, 386,411
Toothpick plant, drugs derived from, 883
TOPAS, 192
TOPKAT, 246
Topographical data, 411
Topographical **mimetics** (peptidomimetics), 636
Topoisomerase **II** inhibitors, 717
Topological descriptors
for druglikeness screening, 247–249
estimation systems, 388–389
with QSAR, 54–55
Topotecan, 848,849,861
Torsional potential, 80
Toxicity databases, 246,386
development, 828–829
Toxicity prediction, 827–843
Toxicity screening
as bottleneck in drug discovery, 592
and functional group filters, 246–247
pulsed **ultrafiltration** application, 605
Toxicophores, **829–831**
associated with allergic contact dermatitis, 830
C-Toxiferine 1, 856,857
TPCK, 760–761,762
Tramadol, 782
chromatographic separation, 792
classical resolution, 795–796
metabolism, 786–787
Transesterification
enzyme-mediated asymmetric, 805–806
Transferred NOE technique, 532
and NMR screening, 572–573
Transition-state analog enzyme inhibitors, 720, 748–754
Transition state analog inhibitors, 646
peptide bond isosteres, 644
7-Transmembrane **G-protein-coupled** receptors, 229–234
Transpeptidase inhibitors, 717
Transverse relaxation-optimized spectroscopy (**TROSY**), 515
for macromolecular structure determination, 533,534
Trees, **376–377, 411**
TrEMBL, 335,346
Triazines
QSAR studies of cellular growth inhibition, 37–38
QSAR studies of DHFR inhibition, 31–33
Trimethoprim, 717, 719
interaction with dihydrofolate reductase, 151,183
structure-based design, 425
***α,ω*-*bis*-Trimethylammonium** polymethylene compounds, 710
Trimetrexate
interaction with dihydrofolate reductase, NMR spectroscopy, 531,557–559
Triple resonance spectra, 514
Tripos, Inc. databases, 387
Tripos force field, 80

t-RNA guanine transglycosylase inhibitors
novel lead identification, 321
Trojan horse inactivators, 756
Trypsin inhibitors
molecular modeling, 120
QSAR studies, 5, 25
site-based pharmacophores, 235–236
Trypsinogen inhibitors
molecular modeling, 116
Tryptophan
chemical modification reagents, 755
TSCA database, 386
Tubby gene
X-ray crystallographic function elucidation, 494
Tube curare, 856
D-Tubocurarine
drugs derived from, 856,857
fragment analogs, 708–710
β-Tubulin
X-ray crystallographic studies, 483
Tumor necrosis factor receptor 1
X-ray crystallographic studies, 493
2D descriptors
molecular similarityldiversity methods, 191–194
with QSAR, 54–55
validation, 211–213
2D pharmacophore searching, 383
filter cascade, 267
virtual screening, 255
2D quantitative structure-activity relationships (2D-QSAR), 52, 53
2D query features, 397
2D structures, 364–366, 397
conversion of names to, 373
2-Point pharmacophores, 376
Tyrosine
chemical modification reagents, 755
Tyrosine kinase inhibitors
molecular modeling, 130

U-85548
structure-based design, 436–437,438
Ugi reaction, 229,231, 232, 236
UK QSAR and Cheminformatics Group, 360
Ukrain, 849
Uncompetitive inhibitors, 729–730
Unicode, 411
UNITY, 259,377
descriptors, 192,201
in molecular modeling, 111
novel lead identification, 320
UNITY 2D, 212
UNITY 3D, 363,387
University of Manchester Bioinformatics Education and Research site (UMBER), 335
Unix, 396, 411
Unsupervised data mining, 66–67,412
Urea
pharmacophore points, 249
Ureido resonance, 182
USEPA Suite, 390

VALIDATE, 116,310
Vancomycin, 770
Vancomycin-peptide complex
binding affinity, 119
van der Waals forces, 174,285
and docking scoring, 308
enzyme inhibitors, 723–724
and molar refraction, 24
molecular modeling, 79–80, 81, 82, 89
and QSAR, 6, 7
van der Waals radius, 79, 81, 173
Vanillin
antisickling agent, 419–420
Vanilloid receptors, 853–854
VanX inhibitors, 770–771, 772
VARCHAR data type, 412
VARCHAR2 data type, 412
Vector maps, 140–142
Verapamil
classical resolution, 798
Verapamilic acid, 798
Vidarabine, 717
Vigabatrin, 718,766, 767,782
Vinblastine, 858–859,860
Vinca alkaloids, 858–860
Vincristine, 858–859,860
Vindesine, 859–860
Vinorelbine, 849
Viracept, 659
structure-based design, 440, 442
Viral DNA polymerase inhibitors, 717
Virtual chemistry space, 67
Virtual libraries, 237, 283,315
handling large, 220–221
and QSAR, 61
Virtual rings, 91
Virtual screening, 244–245, 271–274,315–317,412. See also Docking methods; Scoring functions
applications, 267–271
basic concepts, 289–290
combinatorial docking, 317–318
consensus scoring, 265–266, 291,319–320
docking as virtual screening tool, 266–267
druglikeness screening, 245–250
filter cascade, 267
focused screening libraries for lead identification, 250–252
hydrogen bonding and hydrophobic interactions, 319
ligand-based, 188,209–214
molecular similarityldiversity methods for, 188, 190, 209–214
novel lead identification, 320–321
pharmacophore screening, 252–260
QSAR as tool for, 66–69
seeding experiments, 318–319
structure-based, 260–267
weak inhibitors, 319
Vista search program, 387
Vitamin D receptor
X-ray crystallographic studies, 493
VK19911
structure-based design, 458
Voglibose, 849
VolSurf program, 202
Volume
molecular dynamic simulation, 96
Volume mapping, 139–140
Voronoi QSAR technique, 53
VRML (Virtual Reality Markup Language), 405
VX-497
structure-based design, 447
VX-745
structure-based design, 458

Warfarin, 882–883
enantiomers, 786

Warfarin *(Continued)*
HIV protease inhibitor, 659, 661
nonclassical resolution, 801
wARP, 478
Water
gas phase association thermodynamic functions, 178
importance of bound in structure-based design, 409
molecular modeling, 85
octanol/water partitioning system, 16–17
and protein-ligand interactions, 288
role in docking, 302–303, 313–314
solvating effect in enzyme inhibitors, 722–723
Wellcome Registry, 222
White-Bovill force field, 80
WIN-35065-2
dopamine transporter inhibitor, 268
WIN-51711
structure-based design, 454–455
WIN-54954
structure-based design, 455
WIN-63843
structure-based design, 455–456
Wiswesser line notation, 368–369
WIZARD, 255,260
World Drug Index (WDI), 379, 386,387
World Patents Index (WPI), 386

Xanthine-guanine phosphoribosyltransferase
X-ray crystallographic studies, 493
Xanthine oxidase inhibitors, 718
XFIT graphics program, 478
Ximelagatran
structure-based design, 442
XML (extensible Markup Language), 371,405,412
XMLQuery, 412
X-ray crystallography, 351, 471–473,612
applications, 479–481
crystallization for, 473–474, 480–481
databases for, 478–479
data collection, 474–476
drug targets with published structures, 482–493
and molecular modeling, 78
phase problem, 476–478
and QSAR, 5
and structural genomics, 481, 494–496
in structure-based drug design, 418,419,420
and structure-based library design, 225
and virtual screening, 244
X-ray diffraction, 472–473, 614
X-ray lenses, 612

Yellow sweet clover, drugs derived from, 882
Yew tree, paclitaxel from, 861–862
YM-022,856
Yukawa-Tsuno equation, 14

Z-100,849
Zanamivir, 717
structure-based design, 451
Ziconotide
NMR spectroscopy, 518–523, 526,534
Zidovudine, 717
Zingerone
allergenicity prediction, 835



"An essential addition to the libraries of any medicinal chemist . . . an outstanding work . . . highly praised as a fountain of information in drug studies and research."

—*Journal of Medicinal Chemistry* on the *Fifth Edition*

This new edition of Dr. Alfred Burger's internationally celebrated classic helps researchers acquaint themselves with both traditional and state-of-the-art principles and practices governing new medicinal drug research and development. Completely updated and revised to reflect the many monumental changes that have occurred in the field, this latest edition brings together contributions by experts in a wide range of related fields to explore recent advances in the understanding of the structural biology of drug action, as well as cutting-edge technologies for drug discovery now in use around the world.

This *Sixth Edition* of *Burger's Medicinal Chemistry and Drug Discovery* has been expanded to six volumes:

Volume 1: Drug Discovery
Volume 2: Drug Discovery and Drug Development
Volume 3: Cardiovascular Agents and Endocrines
Volume 4: Autocoids, Diagnostics, and Drugs from New Biology
Volume 5: Chemotherapeutic Agents
Volume 6: Nervous System Agents

DONALD A. ABRAHAM, PHD, is Professor and Chairman of the Department of Medicinal Chemistry at the Virginia Commonwealth University School of Pharmacy. A world-renowned leader in medicinal chemistry and biotechnology, he is the author of more than 140 journal citations and twenty-five patents. He was selected by the AACP Board of Directors as the recipient of the 2002 AACP Paul Dawson Biotechnology Award.

Cover Design: David Levy

WILEY-INTERSCIENCE
wiley.com

ISBN 0-471-27090-3
90000
9 780471 270904